Table I-3
SUMMARY OF CHANGES IN CANCER INCIDENCE AND MORTALITY, 1950-2001 AND
5-YEAR RELATIVE SURVIVAL RATES, 1950-2000
Males and Females, By Primary Cancer Site

Table is temporarily unavailable.
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>All Sites</td>
<td>470.3</td>
<td>554.3</td>
<td>414.4</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lip</td>
<td>1.0</td>
<td>1.7</td>
<td>0.4</td>
</tr>
<tr>
<td>Tongue</td>
<td>2.5</td>
<td>3.7</td>
<td>1.6</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>1.2</td>
<td>1.6</td>
<td>1.0</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>0.8</td>
<td>1.2</td>
<td>0.5</td>
</tr>
<tr>
<td>Gum &amp; other</td>
<td>1.7</td>
<td>2.0</td>
<td>1.4</td>
</tr>
<tr>
<td>Oral cavity</td>
<td>0.7</td>
<td>1.0</td>
<td>0.4</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>1.3</td>
<td>2.1</td>
<td>0.5</td>
</tr>
<tr>
<td>Tonsil</td>
<td>0.3</td>
<td>0.5</td>
<td>0.2</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>0.8</td>
<td>1.4</td>
<td>0.3</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>0.3</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td>Other oral cavity &amp; pharynx</td>
<td>0.3</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td>Digestive System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver &amp; Intrahep:</td>
<td>6.0</td>
<td>9.1</td>
<td>3.5</td>
</tr>
<tr>
<td>Liver</td>
<td>5.1</td>
<td>8.0</td>
<td>2.8</td>
</tr>
<tr>
<td>Intrahep bile duct</td>
<td>1.8</td>
<td>1.1</td>
<td>0.2</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>1.2</td>
<td>0.8</td>
<td>1.6</td>
</tr>
<tr>
<td>Other biliary</td>
<td>1.6</td>
<td>2.0</td>
<td>1.3</td>
</tr>
<tr>
<td>Pancreas</td>
<td>11.0</td>
<td>12.6</td>
<td>9.7</td>
</tr>
<tr>
<td>Retroperitoneum</td>
<td>0.4</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Peritoneum, omentum &amp; mesentery</td>
<td>0.7</td>
<td>0.2</td>
<td>1.0</td>
</tr>
<tr>
<td>Other digestive system</td>
<td>0.5</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Respiratory System:</td>
<td>67.3</td>
<td>88.7</td>
<td>51.5</td>
</tr>
<tr>
<td>Nose, nasal cavity &amp; middle ear</td>
<td>0.7</td>
<td>0.9</td>
<td>0.5</td>
</tr>
<tr>
<td>Larynx</td>
<td>3.8</td>
<td>6.7</td>
<td>1.4</td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>61.7</td>
<td>79.1</td>
<td>49.1</td>
</tr>
<tr>
<td>Pleura</td>
<td>0.9</td>
<td>1.8</td>
<td>0.3</td>
</tr>
<tr>
<td>Trachea &amp; other respiratory organs</td>
<td>0.2</td>
<td>0.3</td>
<td>0.1</td>
</tr>
<tr>
<td>Bones &amp; joints</td>
<td>0.9</td>
<td>1.0</td>
<td>0.8</td>
</tr>
<tr>
<td>Soft tissue (incl heart)</td>
<td>2.9</td>
<td>3.5</td>
<td>2.4</td>
</tr>
<tr>
<td>Skin (ex basal &amp; squam)</td>
<td>19.6</td>
<td>25.3</td>
<td>15.4</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>17.0</td>
<td>21.4</td>
<td>13.8</td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>2.6</td>
<td>3.9</td>
<td>1.5</td>
</tr>
<tr>
<td>Breast</td>
<td>73.9</td>
<td>1.2</td>
<td>135.2</td>
</tr>
<tr>
<td>Breast (in situ)</td>
<td>16.1</td>
<td>0.2</td>
<td>30.0</td>
</tr>
</tbody>
</table>

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

- SEER 12 areas.
- NHIS public use data file for the total US.
- SEER 9 areas.
- Statistic could not be calculated due to less than 25 cases in the time interval.
Table I-4 - continued

AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES

By Primary Cancer Site, Sex and Time Period

All Races

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>Female Genital System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>27.8</td>
<td>51.3</td>
<td>9.5</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>13.1</td>
<td>9.3</td>
<td>1.6</td>
</tr>
<tr>
<td>Uterus, NOS</td>
<td>0.3</td>
<td>0.4</td>
<td>1.2</td>
</tr>
<tr>
<td>Ovary</td>
<td>7.6</td>
<td>13.9</td>
<td>5.0</td>
</tr>
<tr>
<td>Vagina</td>
<td>0.4</td>
<td>0.7</td>
<td>0.1</td>
</tr>
<tr>
<td>Vulva</td>
<td>1.3</td>
<td>2.3</td>
<td>0.3</td>
</tr>
<tr>
<td>Other female</td>
<td>0.4</td>
<td>0.7</td>
<td>0.1</td>
</tr>
<tr>
<td>Male Genital System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testis</td>
<td>78.2</td>
<td>178.7</td>
<td></td>
</tr>
<tr>
<td>Penis</td>
<td>75.0</td>
<td>172.3</td>
<td></td>
</tr>
<tr>
<td>Male nervous system</td>
<td>2.6</td>
<td>5.2</td>
<td></td>
</tr>
<tr>
<td>Other male</td>
<td>0.3</td>
<td>0.8</td>
<td></td>
</tr>
<tr>
<td>Urinary System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary bladder</td>
<td>32.6</td>
<td>53.1</td>
<td>17.4</td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis</td>
<td>20.4</td>
<td>36.1</td>
<td>9.1</td>
</tr>
<tr>
<td>Ureter</td>
<td>11.3</td>
<td>15.7</td>
<td>7.8</td>
</tr>
<tr>
<td>Male nervous system</td>
<td>0.5</td>
<td>0.8</td>
<td>0.4</td>
</tr>
<tr>
<td>Other urinary system</td>
<td>0.3</td>
<td>0.5</td>
<td>0.2</td>
</tr>
<tr>
<td>Eye &amp; Orbit</td>
<td>0.7</td>
<td>0.9</td>
<td>0.6</td>
</tr>
<tr>
<td>Brain &amp; Nervous System:&lt;sup&gt;d&lt;/sup&gt;</td>
<td>6.4</td>
<td>7.6</td>
<td>5.3</td>
</tr>
<tr>
<td>Brain</td>
<td>6.0</td>
<td>7.2</td>
<td>4.9</td>
</tr>
<tr>
<td>Cranial nerves &amp; other nervous system</td>
<td>0.4</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Endocrine System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thymus</td>
<td>7.8</td>
<td>4.5</td>
<td>11.0</td>
</tr>
<tr>
<td>Other endocrine &amp; thymus</td>
<td>7.2</td>
<td>3.8</td>
<td>10.4</td>
</tr>
<tr>
<td>Lymphoma:</td>
<td>21.7</td>
<td>26.2</td>
<td>18.1</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>2.7</td>
<td>3.0</td>
<td>2.4</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>19.1</td>
<td>23.3</td>
<td>15.7</td>
</tr>
<tr>
<td>Myeloma</td>
<td>5.6</td>
<td>6.9</td>
<td>4.6</td>
</tr>
<tr>
<td>Leukemia:</td>
<td>12.1</td>
<td>15.9</td>
<td>9.4</td>
</tr>
<tr>
<td>Lymphocytic:</td>
<td>5.5</td>
<td>7.4</td>
<td>4.1</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>1.5</td>
<td>1.7</td>
<td>1.4</td>
</tr>
<tr>
<td>Chronic lymphocytic</td>
<td>3.5</td>
<td>5.0</td>
<td>2.4</td>
</tr>
<tr>
<td>Other lymphocytic</td>
<td>0.5</td>
<td>0.7</td>
<td>0.3</td>
</tr>
<tr>
<td>Myeloid &amp; Monocytic:</td>
<td>5.8</td>
<td>7.5</td>
<td>4.7</td>
</tr>
<tr>
<td>Acute myeloid</td>
<td>3.8</td>
<td>4.7</td>
<td>3.1</td>
</tr>
<tr>
<td>Chronic myeloid</td>
<td>1.6</td>
<td>2.2</td>
<td>1.2</td>
</tr>
<tr>
<td>Acute monocytic</td>
<td>0.3</td>
<td>0.3</td>
<td>0.2</td>
</tr>
<tr>
<td>Other myeloid &amp; monocytic</td>
<td>0.2</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Other:</td>
<td>0.8</td>
<td>1.0</td>
<td>0.7</td>
</tr>
<tr>
<td>Other acute</td>
<td>0.4</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Aileukemic, subleuk &amp; NOS</td>
<td>0.4</td>
<td>0.5</td>
<td>0.3</td>
</tr>
<tr>
<td>Ill-defined &amp; unspecified</td>
<td>10.8</td>
<td>12.4</td>
<td>9.7</td>
</tr>
</tbody>
</table>

Note: Incidence and death rates are per 100,000, and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

<sup>a</sup> SEER 12 areas.
<sup>b</sup> NCHS public use data file for the total US.
<sup>c</sup> SEER 9 areas.
<sup>d</sup> Due to coding changes, Brain & Nervous System mortality are no longer shown separately.
- Statistic could not be calculated due to less than 25 cases in the time interval.
### Table I-5

**AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES**

By Primary Cancer Site, Sex and Time Period

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>All Sites</td>
<td>479.6</td>
<td>556.5</td>
<td>429.8</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx:</td>
<td>10.7</td>
<td>15.7</td>
<td>6.4</td>
</tr>
<tr>
<td>Lip</td>
<td>1.1</td>
<td>2.0</td>
<td>0.4</td>
</tr>
<tr>
<td>Tongue</td>
<td>2.6</td>
<td>3.8</td>
<td>1.6</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>1.3</td>
<td>1.7</td>
<td>1.0</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>0.8</td>
<td>1.2</td>
<td>0.5</td>
</tr>
<tr>
<td>Gum &amp; other</td>
<td>1.7</td>
<td>2.0</td>
<td>1.4</td>
</tr>
<tr>
<td>Oral cavity</td>
<td>0.4</td>
<td>0.6</td>
<td>0.2</td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>1.3</td>
<td>2.2</td>
<td>0.6</td>
</tr>
<tr>
<td>Tonsil</td>
<td>0.3</td>
<td>0.5</td>
<td>0.2</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>0.8</td>
<td>1.4</td>
<td>0.3</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>0.3</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td>Digestive System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver &amp; Intrahep</td>
<td>4.8</td>
<td>7.2</td>
<td>2.9</td>
</tr>
<tr>
<td>Liver</td>
<td>4.0</td>
<td>6.2</td>
<td>2.2</td>
</tr>
<tr>
<td>Intrahep bile duct</td>
<td>0.8</td>
<td>1.1</td>
<td>0.2</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>1.2</td>
<td>0.8</td>
<td>1.5</td>
</tr>
<tr>
<td>Other biliary</td>
<td>1.5</td>
<td>1.9</td>
<td>1.2</td>
</tr>
<tr>
<td>Pancreas</td>
<td>10.8</td>
<td>12.5</td>
<td>9.4</td>
</tr>
<tr>
<td>Retropertitoneum</td>
<td>0.4</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Peritoneum, omentum &amp; mesentery</td>
<td>0.7</td>
<td>0.2</td>
<td>1.1</td>
</tr>
<tr>
<td>Other digestive system</td>
<td>0.5</td>
<td>0.5</td>
<td>0.4</td>
</tr>
<tr>
<td>Respiratory System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nose, nasal cavity &amp; middle ear</td>
<td>0.7</td>
<td>0.9</td>
<td>0.5</td>
</tr>
<tr>
<td>Larynx</td>
<td>3.8</td>
<td>6.6</td>
<td>1.5</td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>62.4</td>
<td>77.9</td>
<td>51.3</td>
</tr>
<tr>
<td>Pleura</td>
<td>1.0</td>
<td>1.9</td>
<td>0.3</td>
</tr>
<tr>
<td>Trachea &amp; other respiratory organs</td>
<td>0.2</td>
<td>0.3</td>
<td>0.1</td>
</tr>
<tr>
<td>Bones &amp; joints</td>
<td>0.9</td>
<td>1.1</td>
<td>0.8</td>
</tr>
<tr>
<td>Soft tissue (incl heart)</td>
<td>2.9</td>
<td>3.5</td>
<td>2.5</td>
</tr>
<tr>
<td>Skin (ex basal &amp; squam)</td>
<td>22.9</td>
<td>29.2</td>
<td>18.4</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>20.3</td>
<td>25.4</td>
<td>16.8</td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>2.6</td>
<td>3.9</td>
<td>1.6</td>
</tr>
<tr>
<td>Breast (in situ)</td>
<td>16.4</td>
<td>2.9</td>
<td>31.0</td>
</tr>
</tbody>
</table>

**Note:** Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

<sup>a</sup> SEER 12 areas.

<sup>b</sup> NCHS public use data file for the total US.

<sup>c</sup> SEER 9 areas.

- Statistic could not be calculated due to less than 25 cases in the time interval.
### Table I-5 - continued

**AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES**  
By Primary Cancer Site, Sex and Time Period

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>Female Genital System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix uteri</td>
<td>28.9</td>
<td>53.8</td>
<td>9.3</td>
</tr>
<tr>
<td>Corpus uteri</td>
<td>13.9</td>
<td>25.7</td>
<td>1.1</td>
</tr>
<tr>
<td>Uterus, NOS</td>
<td>0.2</td>
<td>0.4</td>
<td>1.1</td>
</tr>
<tr>
<td>Ovary</td>
<td>8.0</td>
<td>14.8</td>
<td>5.2</td>
</tr>
<tr>
<td>Vagina</td>
<td>0.4</td>
<td>0.7</td>
<td>0.1</td>
</tr>
<tr>
<td>Vulva</td>
<td>1.4</td>
<td>2.5</td>
<td>0.3</td>
</tr>
<tr>
<td>Other female genital system</td>
<td>0.4</td>
<td>0.7</td>
<td>0.1</td>
</tr>
<tr>
<td>Male Genital System:</td>
<td>77.1</td>
<td>174.7</td>
<td>10.9</td>
</tr>
<tr>
<td>Prostate</td>
<td>73.5</td>
<td>167.4</td>
<td>10.6</td>
</tr>
<tr>
<td>Testis</td>
<td>3.2</td>
<td>6.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Penis</td>
<td>0.3</td>
<td>0.8</td>
<td>0.1</td>
</tr>
<tr>
<td>Other male genital system</td>
<td>0.1</td>
<td>0.3</td>
<td>0.0</td>
</tr>
<tr>
<td>Urinary System:</td>
<td>35.0</td>
<td>57.4</td>
<td>18.4</td>
</tr>
<tr>
<td>Urinary bladder &amp; pelvis</td>
<td>22.5</td>
<td>39.9</td>
<td>9.8</td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis</td>
<td>11.7</td>
<td>16.2</td>
<td>8.1</td>
</tr>
<tr>
<td>Ureter</td>
<td>0.6</td>
<td>0.8</td>
<td>0.4</td>
</tr>
<tr>
<td>Other urinary system</td>
<td>0.3</td>
<td>0.5</td>
<td>0.1</td>
</tr>
<tr>
<td>Eye &amp; Orbit</td>
<td>0.9</td>
<td>1.0</td>
<td>0.7</td>
</tr>
<tr>
<td>Brain &amp; Nervous System:&lt;sup&gt;d&lt;/sup&gt;</td>
<td>7.1</td>
<td>8.4</td>
<td>6.0</td>
</tr>
<tr>
<td>Brain</td>
<td>6.7</td>
<td>8.0</td>
<td>5.5</td>
</tr>
<tr>
<td>Cranial nerves &amp; other</td>
<td>0.4</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>nervous system</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Endocrine System:</td>
<td>8.1</td>
<td>4.7</td>
<td>11.5</td>
</tr>
<tr>
<td>Thyroid</td>
<td>7.5</td>
<td>4.0</td>
<td>10.9</td>
</tr>
<tr>
<td>Other endocrine &amp; thymus</td>
<td>0.6</td>
<td>0.7</td>
<td>0.5</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>23.0</td>
<td>27.6</td>
<td>19.2</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>2.9</td>
<td>3.3</td>
<td>2.6</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>20.1</td>
<td>24.4</td>
<td>16.6</td>
</tr>
<tr>
<td>Myeloma</td>
<td>5.2</td>
<td>6.6</td>
<td>4.2</td>
</tr>
<tr>
<td>Leukemia:</td>
<td>12.9</td>
<td>16.9</td>
<td>9.9</td>
</tr>
<tr>
<td>Lymphocytic:</td>
<td>6.0</td>
<td>8.1</td>
<td>4.4</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>1.6</td>
<td>1.8</td>
<td>1.5</td>
</tr>
<tr>
<td>Chronic lymphocytic</td>
<td>3.9</td>
<td>5.5</td>
<td>2.7</td>
</tr>
<tr>
<td>Other lymphocytic</td>
<td>0.5</td>
<td>0.8</td>
<td>0.3</td>
</tr>
<tr>
<td>Myeloid &amp; Monocytic:</td>
<td>6.0</td>
<td>7.7</td>
<td>4.8</td>
</tr>
<tr>
<td>Acute myeloid</td>
<td>3.9</td>
<td>4.9</td>
<td>3.2</td>
</tr>
<tr>
<td>Chronic myeloid</td>
<td>1.7</td>
<td>2.2</td>
<td>1.3</td>
</tr>
<tr>
<td>Acute monocytic</td>
<td>0.3</td>
<td>0.4</td>
<td>0.2</td>
</tr>
<tr>
<td>Other myeloid &amp; monocytic</td>
<td>0.2</td>
<td>0.2</td>
<td>0.1</td>
</tr>
<tr>
<td>Other:</td>
<td>0.8</td>
<td>1.1</td>
<td>0.7</td>
</tr>
<tr>
<td>Other acute</td>
<td>0.4</td>
<td>0.6</td>
<td>0.4</td>
</tr>
<tr>
<td>Ailkeemic, subleuk &amp; NOS</td>
<td>0.4</td>
<td>0.5</td>
<td>0.3</td>
</tr>
</tbody>
</table>

**Note:** Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

- **a** SEER 12 areas.
- **b** NCHS public use data file for the total US.
- **c** SEER 9 areas.
- **d** Due to coding changes, Brain & Nervous System mortality are no longer shown separately.
- **-** Statistic could not be calculated due to less than 25 cases in the time interval.
### Table I-6

**AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES**

By Primary Cancer Site, Sex and Time Period

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>All Sites</td>
<td>515.8</td>
<td>689.2</td>
<td>401.0</td>
</tr>
<tr>
<td>Oral Cavity &amp; Pharynx:</td>
<td>11.9</td>
<td>19.5</td>
<td>6.2</td>
</tr>
<tr>
<td>Lip</td>
<td>0.2</td>
<td>0.3</td>
<td></td>
</tr>
<tr>
<td>Tongue</td>
<td>2.7</td>
<td>4.5</td>
<td>1.4</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>0.9</td>
<td>1.2</td>
<td>0.8</td>
</tr>
<tr>
<td>Floor of mouth</td>
<td>1.1</td>
<td>2.0</td>
<td>0.5</td>
</tr>
<tr>
<td>Gum &amp; other</td>
<td>2.0</td>
<td>2.9</td>
<td>1.3</td>
</tr>
<tr>
<td>oral cavity</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nasopharynx</td>
<td>0.6</td>
<td>1.0</td>
<td>0.4</td>
</tr>
<tr>
<td>Tonsil</td>
<td>1.9</td>
<td>3.5</td>
<td>0.7</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>0.6</td>
<td>1.2</td>
<td>-</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>1.3</td>
<td>2.5</td>
<td>0.5</td>
</tr>
<tr>
<td>Other oral cavity &amp; pharynx</td>
<td>0.5</td>
<td>0.9</td>
<td>-</td>
</tr>
<tr>
<td>Digestive System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver &amp; Intrahep:</td>
<td>7.2</td>
<td>11.8</td>
<td>3.9</td>
</tr>
<tr>
<td>Liver</td>
<td>6.6</td>
<td>10.8</td>
<td>3.5</td>
</tr>
<tr>
<td>Intrahep bile duct</td>
<td>0.6</td>
<td>0.9</td>
<td>0.4</td>
</tr>
<tr>
<td>Gallbladder</td>
<td>1.2</td>
<td>0.7</td>
<td>1.5</td>
</tr>
<tr>
<td>Other biliary</td>
<td>1.3</td>
<td>1.6</td>
<td>1.1</td>
</tr>
<tr>
<td>Pancreas</td>
<td>15.4</td>
<td>17.1</td>
<td>13.9</td>
</tr>
<tr>
<td>Retropertitoneum</td>
<td>0.4</td>
<td>0.4</td>
<td>0.4</td>
</tr>
<tr>
<td>Peritoneum, omentum &amp; mesentery</td>
<td>0.4</td>
<td>0.6</td>
<td>0.6</td>
</tr>
<tr>
<td>Other digestive system</td>
<td>0.5</td>
<td>0.6</td>
<td>0.5</td>
</tr>
<tr>
<td>Respiratory System:</td>
<td>87.8</td>
<td>131.6</td>
<td>57.9</td>
</tr>
<tr>
<td>Nose, nasal cavity &amp; middle ear</td>
<td>0.7</td>
<td>0.9</td>
<td>0.6</td>
</tr>
<tr>
<td>Larynx</td>
<td>6.4</td>
<td>12.1</td>
<td>2.4</td>
</tr>
<tr>
<td>Lung &amp; bronchus</td>
<td>79.8</td>
<td>117.2</td>
<td>54.5</td>
</tr>
<tr>
<td>Pleura</td>
<td>0.6</td>
<td>1.0</td>
<td>-</td>
</tr>
<tr>
<td>Trachea &amp; other respiratory organs</td>
<td>0.3</td>
<td>0.4</td>
<td>-</td>
</tr>
<tr>
<td>Bones &amp; joints</td>
<td>0.7</td>
<td>0.8</td>
<td>0.6</td>
</tr>
<tr>
<td>Soft tissue (incl heart)</td>
<td>3.1</td>
<td>3.7</td>
<td>2.6</td>
</tr>
<tr>
<td>Skin (ex basal &amp; squam):</td>
<td>3.9</td>
<td>6.1</td>
<td>2.1</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>1.0</td>
<td>1.5</td>
<td>0.7</td>
</tr>
<tr>
<td>Other non-epithelial skin</td>
<td>2.9</td>
<td>4.6</td>
<td>1.4</td>
</tr>
<tr>
<td>Breast</td>
<td>69.2</td>
<td>1.9</td>
<td>119.9</td>
</tr>
<tr>
<td>Breast (in situ)</td>
<td>15.6</td>
<td>-</td>
<td>27.4</td>
</tr>
</tbody>
</table>

Note: Incidence and death rates are per 100,000 and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

- <sup>a</sup> SEER 12 areas.
- <sup>b</sup> NCHS public use data file for the total US.
- <sup>c</sup> SEER 9 areas.
- Statistic could not be calculated due to less than 25 cases in the time interval.
Table I-6 - continued

AGE-ADJUSTED SEER INCIDENCE AND U.S. DEATH RATES AND 5-YEAR RELATIVE SURVIVAL RATES
By Primary Cancer Site, Sex and Time Period

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>Female Genital System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cervix uteri:</td>
<td>25.1</td>
<td>43.5</td>
<td>12.5</td>
</tr>
<tr>
<td>Corpus uteri:</td>
<td>6.7</td>
<td>11.8</td>
<td>3.2</td>
</tr>
<tr>
<td>Uterus, NOS:</td>
<td>10.1</td>
<td>17.5</td>
<td>1.9</td>
</tr>
<tr>
<td>Ovary:</td>
<td>5.8</td>
<td>10.1</td>
<td>4.5</td>
</tr>
<tr>
<td>Vagina:</td>
<td>0.6</td>
<td>1.1</td>
<td>0.2</td>
</tr>
<tr>
<td>Vulva:</td>
<td>1.0</td>
<td>1.7</td>
<td>0.2</td>
</tr>
<tr>
<td>Other female:</td>
<td>0.4</td>
<td>0.6</td>
<td>0.2</td>
</tr>
<tr>
<td>Male Genital System:</td>
<td>112.5</td>
<td>274.0</td>
<td>24.7</td>
</tr>
<tr>
<td>Prostate:</td>
<td>111.3</td>
<td>271.3</td>
<td>24.5</td>
</tr>
<tr>
<td>Testis:</td>
<td>0.7</td>
<td>1.5</td>
<td>0.1</td>
</tr>
<tr>
<td>Penis:</td>
<td>0.3</td>
<td>0.9</td>
<td>0.1</td>
</tr>
<tr>
<td>Other male:</td>
<td>0.1</td>
<td>0.3</td>
<td>0.0</td>
</tr>
<tr>
<td>Urinary System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary bladder:</td>
<td>26.8</td>
<td>40.5</td>
<td>17.7</td>
</tr>
<tr>
<td>Kidney &amp; renal pelvis:</td>
<td>12.6</td>
<td>20.4</td>
<td>7.7</td>
</tr>
<tr>
<td>Ureter:</td>
<td>13.3</td>
<td>18.8</td>
<td>9.4</td>
</tr>
<tr>
<td>Other urinary system:</td>
<td>0.3</td>
<td>1.1</td>
<td>0.1</td>
</tr>
<tr>
<td>Eye &amp; Orbit:</td>
<td>0.2</td>
<td>-</td>
<td>0.0</td>
</tr>
<tr>
<td>Brain &amp; Nervous System:</td>
<td>4.0</td>
<td>4.6</td>
<td>3.4</td>
</tr>
<tr>
<td>Cranial nerves &amp; other nervous system:</td>
<td>3.5</td>
<td>4.2</td>
<td>3.0</td>
</tr>
<tr>
<td>Endocrine System:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thyroid:</td>
<td>4.7</td>
<td>2.8</td>
<td>6.3</td>
</tr>
<tr>
<td>Other endocrine &amp; thymus:</td>
<td>4.1</td>
<td>2.2</td>
<td>5.7</td>
</tr>
<tr>
<td>Lymphoma:</td>
<td>17.0</td>
<td>21.2</td>
<td>13.7</td>
</tr>
<tr>
<td>Hodgkin lymphoma:</td>
<td>2.4</td>
<td>2.9</td>
<td>2.0</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma:</td>
<td>14.6</td>
<td>18.3</td>
<td>11.7</td>
</tr>
<tr>
<td>Myeloma:</td>
<td>11.0</td>
<td>12.9</td>
<td>9.8</td>
</tr>
<tr>
<td>Leukemia:</td>
<td>9.9</td>
<td>12.8</td>
<td>7.9</td>
</tr>
<tr>
<td>Lymphocytic:</td>
<td>3.9</td>
<td>5.3</td>
<td>2.9</td>
</tr>
<tr>
<td>Acute lymphocytic:</td>
<td>0.8</td>
<td>0.9</td>
<td>0.7</td>
</tr>
<tr>
<td>Chronic lymphocytic:</td>
<td>2.8</td>
<td>4.0</td>
<td>2.0</td>
</tr>
<tr>
<td>Other lymphocytic:</td>
<td>0.3</td>
<td>-</td>
<td>0.1</td>
</tr>
<tr>
<td>Myeloid &amp; Monocytic:</td>
<td>5.3</td>
<td>6.6</td>
<td>4.4</td>
</tr>
<tr>
<td>Acute myeloid:</td>
<td>3.4</td>
<td>4.1</td>
<td>2.9</td>
</tr>
<tr>
<td>Chronic myeloid:</td>
<td>1.5</td>
<td>2.1</td>
<td>1.1</td>
</tr>
<tr>
<td>Acute monocytic:</td>
<td>0.2</td>
<td>-</td>
<td>0.0</td>
</tr>
<tr>
<td>Other myeloid &amp; monocytic:</td>
<td>0.2</td>
<td>-</td>
<td>0.1</td>
</tr>
<tr>
<td>Other:</td>
<td>0.7</td>
<td>0.9</td>
<td>0.7</td>
</tr>
<tr>
<td>Other acute:</td>
<td>0.4</td>
<td>0.5</td>
<td>0.3</td>
</tr>
<tr>
<td>AIE leukemic, subleuk &amp; NOS:</td>
<td>0.4</td>
<td>-</td>
<td>0.4</td>
</tr>
<tr>
<td>Ill-defined &amp; unspecified:</td>
<td>13.7</td>
<td>16.2</td>
<td>12.0</td>
</tr>
</tbody>
</table>

Note: Incidence and death rates are per 100,000, and are age-adjusted to the 2000 U.S. standard population by 5-year age groups. Survival rates are expressed as percents.

a SEER 12 areas.
b NCHS public use data file for the total US.
c SEER 9 areas.
d Due to coding changes, Brain & Nervous System mortality are no longer shown separately.
- Statistic could not be calculated due to less than 25 cases in the time interval.
SEER Incidence* and US Death Rates,# 1997-2001
5-Year Relative Survival Rates,^ 1995-2000
All Cancer Combined, by Race and Sex

* Incidence rates are from the SEER 12 areas and are age-adjusted to the 2000 US standard population by 5-year age groups.
# Death rates are from the NCHS public use data file for the total US and are age-adjusted to the 2000 US standard population by 5-year age groups.
^ Survival rates are from the SEER 9 areas. Relative survival rates are expressed as percents.
Figure I-11

5-Year Relative Survival Rates
SEER Program, 1995-2000
Both Sexes, by Race

Source: SEER 9 areas.
**Table II-4**

ALL SITES (Invasive)

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR AND AGE

<table>
<thead>
<tr>
<th></th>
<th>All Races</th>
<th></th>
<th>Whites</th>
<th></th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td>Total</td>
<td>Males</td>
</tr>
<tr>
<td>5-YR RELATIVE SURVIVAL RATES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YEAR OF DIAGNOSIS:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1960-1963&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>39</td>
<td>-</td>
</tr>
<tr>
<td>1970-1973&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>43</td>
<td>-</td>
</tr>
<tr>
<td>1974-1976&lt;sup&gt;b&lt;/sup&gt;</td>
<td>49.6</td>
<td>41.1</td>
<td>57.1</td>
<td>50.6</td>
<td>42.2</td>
</tr>
<tr>
<td>1977-1979&lt;sup&gt;b&lt;/sup&gt;</td>
<td>50.1</td>
<td>43.3</td>
<td>56.3</td>
<td>51.2</td>
<td>44.7</td>
</tr>
<tr>
<td>1980-1982&lt;sup&gt;b&lt;/sup&gt;</td>
<td>51.0</td>
<td>45.3</td>
<td>56.3</td>
<td>52.1</td>
<td>46.7</td>
</tr>
<tr>
<td>1983-1985&lt;sup&gt;b&lt;/sup&gt;</td>
<td>52.5</td>
<td>46.9</td>
<td>57.8</td>
<td>53.9</td>
<td>48.6</td>
</tr>
<tr>
<td>1986-1988&lt;sup&gt;b&lt;/sup&gt;</td>
<td>55.3</td>
<td>50.1</td>
<td>60.4</td>
<td>56.8</td>
<td>51.9</td>
</tr>
<tr>
<td>1989-1991&lt;sup&gt;b&lt;/sup&gt;</td>
<td>58.8</td>
<td>56.1</td>
<td>61.6</td>
<td>60.3</td>
<td>57.8</td>
</tr>
<tr>
<td>1992-1994&lt;sup&gt;b&lt;/sup&gt;</td>
<td>62.3</td>
<td>62.1</td>
<td>62.6</td>
<td>63.8</td>
<td>63.8</td>
</tr>
<tr>
<td>1995-2000&lt;sup&gt;b&lt;/sup&gt;</td>
<td>64.1&lt;sup&gt;c&lt;/sup&gt;</td>
<td>64.0&lt;sup&gt;c&lt;/sup&gt;</td>
<td>64.3&lt;sup&gt;c&lt;/sup&gt;</td>
<td>65.5&lt;sup&gt;c&lt;/sup&gt;</td>
<td>65.5&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

5-YR RELATIVE SURVIVAL RATES, 1995-2000<sup>b</sup>

| AGE AT DIAGNOSIS:             |           |                          |        |                          |        |          |
| <45                            | 75.5      | 68.6                     | 80.3   | 78.2                     | 72.1   | 82.6     |
| 45-54                          | 68.3      | 61.6                     | 75.2   | 71.5                     | 63.9   | 77.2     |
| 55-64                          | 65.9      | 65.4                     | 66.5   | 67.4                     | 66.9   | 67.9     |
| 65-74                          | 63.0      | 66.7                     | 58.3   | 64.1                     | 67.7   | 59.5     |
| 75+                            | 53.1      | 57.6                     | 49.2   | 54.2                     | 58.6   | 50.5     |
| Under 65                       | 69.4      | 65.0                     | 73.4   | 71.4                     | 67.2   | 75.1     |
| 65 and over                    | 59.0      | 63.4                     | 54.1   | 60.0                     | 64.4   | 55.3     |

* Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>a</sup> Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

<sup>b</sup> The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).

<sup>c</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>d</sup> The standard error of the survival rate is greater than 10 percentage points.

<sup>e</sup> Statistic could not be calculated.
Table III-4
BRAIN AND OTHER NERVOUS SYSTEM CANCER (Invasive)
SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

| 5-YR RELATIVE SURVIVAL RATES | All Races | | Whites | | Blacks |
|------------------------------|----------|----------|--------|--------|
|                              |          |          |        |        |
| Total                        | Males    | Females  |        |        |
| 1960-1963\(^a\)             | –        | –        | –      | 18     | 16     | 21     |
| 1970-1973\(^a\)             | –        | –        | –      | 20     | 18     | 22     |
| 1974-1976\(^b\)             | 22.3     | 20.4     | 24.7   | 22.1   | 20.4   | 24.2   |
| 1977-1979\(^b\)             | 24.6     | 23.0     | 26.5   | 23.9   | 22.5   | 25.7   |
| 1980-1982\(^b\)             | 25.4     | 24.5     | 26.5   | 24.6   | 23.8   | 25.7   |
| 1983-1985\(^b\)             | 26.6     | 25.3     | 28.3   | 26.0   | 24.9   | 27.3   |
| 1986-1988\(^b\)             | 30.8     | 29.1     | 32.8   | 30.1   | 28.0   | 32.6   |
| 1989-1991\(^b\)             | 31.0     | 31.3     | 30.6   | 30.2   | 30.1   | 30.3   |
| 1992-1994\(^b\)             | 32.8     | 33.5     | 31.9   | 32.1   | 32.5   | 31.5   |
| 1995-2000\(^b\)             | 33.0\(^c\) | 32.7\(^c\) | 33.4\(^c\) | 32.2\(^c\) | 32.0\(^c\) | 32.5\(^c\) |

| 5-YR RELATIVE SURVIVAL RATES, 1995-2000\(^d\) | All Races | | Whites | | Blacks |
| Age at Diagnosis: |          |          |        |        |
| <45              | 62.7     | 61.1     | 64.8   | 63.3   | 62.0   | 65.0   |
| 45-54            | 25.0     | 22.9     | 28.4   | 25.0   | 22.6   | 29.2   |
| 55-64            | 14.0     | 13.8     | 14.3   | 13.6   | 13.5   | 13.8   |
| 65-74            | 6.8      | 6.4      | 7.2    | 6.8    | 6.1    | 7.7    |
| 75+              | 3.9      | 3.7      | 4.0    | 3.5    | 3.1    | 3.9    |
| Under 65         | 43.3     | 41.4     | 46.1   | 42.9   | 41.1   | 45.6   |
| 65 and over      | 5.6      | 5.4      | 5.7    | 5.5    | 5.0    | 5.9    |

\(^a\) Rates are based on End Results data from a series of hospital registries and one population-based registry.
\(^b\) Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.
\(^c\) The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).
\(^d\) The standard error of the survival rate is greater than 10 percentage points.
\(^e\) Statistic could not be calculated.
Table IV-7
FEMALE BREAST CANCER (Invasive)
SURVIVAL RATES, BY RACE, DIAGNOSIS YEAR, STAGE AND AGE

<table>
<thead>
<tr>
<th></th>
<th>All Races, Females</th>
<th>White Females</th>
<th>Black Females</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All &lt;50 50+</td>
<td>All &lt;50 50+</td>
<td>All &lt;50 50+</td>
</tr>
<tr>
<td>YEAR OF DIAGNOSIS:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1960-1963a</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1970-1973a</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1974-1976a</td>
<td>74.7 76.4 74.1</td>
<td>75.3 77.4 74.6</td>
<td>63.2 64.2 62.6</td>
</tr>
<tr>
<td>1977-1979a</td>
<td>74.7 75.8 74.4</td>
<td>75.5 76.8 75.1</td>
<td>63.1 65.3 61.8</td>
</tr>
<tr>
<td>1980-1982a</td>
<td>76.3 77.1 76.1</td>
<td>77.1 77.9 76.9</td>
<td>65.8 68.7 64.1</td>
</tr>
<tr>
<td>1983-1985a</td>
<td>78.1 77.4 78.4</td>
<td>79.3 79.0 79.3</td>
<td>63.6 63.5 63.6</td>
</tr>
<tr>
<td>1986-1988a</td>
<td>82.8 80.1 83.8</td>
<td>83.9 81.5 84.7</td>
<td>69.2 67.4 70.1</td>
</tr>
<tr>
<td>1989-1991a</td>
<td>84.9 82.7 85.8</td>
<td>86.2 84.6 86.8</td>
<td>71.2 69.3 72.5</td>
</tr>
<tr>
<td>1992-1994a</td>
<td>86.2 83.9 87.0</td>
<td>87.5 85.9 88.1</td>
<td>72.5 70.0 74.0</td>
</tr>
<tr>
<td>1995-2000a</td>
<td>87.7 85.5 88.5</td>
<td>88.9 87.3 89.5</td>
<td>75.2 72.9 76.8</td>
</tr>
<tr>
<td></td>
<td>87.7c 85.5c 88.5c</td>
<td>88.9c 87.3c 89.5c</td>
<td>75.2c 72.9c 76.8c</td>
</tr>
<tr>
<td>1995-2000b</td>
<td>87.7 85.5 88.5</td>
<td>88.9 87.3 89.5</td>
<td>75.2 72.9 76.8</td>
</tr>
<tr>
<td></td>
<td>87.7 85.5 88.5</td>
<td>88.9 87.3 89.5</td>
<td>75.2 72.9 76.8</td>
</tr>
<tr>
<td>ALL STAGES</td>
<td>87.7 85.5 88.5</td>
<td>88.9 87.3 89.5</td>
<td>75.2 72.9 76.8</td>
</tr>
<tr>
<td>LOCALIZED</td>
<td>97.5 94.4 98.6</td>
<td>98.1 95.1 99.0</td>
<td>91.1 88.5 92.6</td>
</tr>
<tr>
<td>REGIONAL</td>
<td>80.4 80.7 80.3</td>
<td>82.0 83.1 81.6</td>
<td>67.8 66.3 69.1</td>
</tr>
<tr>
<td>DISTANT</td>
<td>25.5 32.5 23.0</td>
<td>27.0 36.2 24.1</td>
<td>14.7 17.8 12.9</td>
</tr>
<tr>
<td>UNSTAGED</td>
<td>54.9 65.4 51.6</td>
<td>55.7 68.3 52.1</td>
<td>49.6 54.1d 46.2d</td>
</tr>
<tr>
<td>IN SITUf</td>
<td>100.0 100.0 100.0</td>
<td>100.0 100.0 100.0</td>
<td>100.0 98.7 100.0</td>
</tr>
</tbody>
</table>

STAGE DISTRIBUTION (%) 1995-2000b

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>91,516 22,676 68,840</td>
<td>77,492 17,924 59,568</td>
<td>7,754 2,759 4,995</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Percent</td>
<td>100% 100% 100%</td>
<td>100% 100% 100%</td>
<td>100% 100% 100%</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LOCALIZED</td>
<td>63 56 66</td>
<td>64 57 66</td>
<td>53 49 56</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>REGIONAL</td>
<td>29 37 26</td>
<td>28 36 26</td>
<td>39 40 32</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DISTANT</td>
<td>6 5 6</td>
<td>5 5 6</td>
<td>9 8 9</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UNSTAGED</td>
<td>2 2 2</td>
<td>2 2 2</td>
<td>3 3 4</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5-YR RELATIVE SURVIVAL RATES, 1995-2000b

<table>
<thead>
<tr>
<th>AGE AT DIAGNOSIS:</th>
<th>All &lt;50 50+</th>
<th>All &lt;50 50+</th>
<th>All &lt;50 50+</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;45</td>
<td>84.0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>45-54</td>
<td>88.0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>55-64</td>
<td>88.8</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>65-74</td>
<td>89.7</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>75+</td>
<td>86.9</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Under 65</td>
<td>87.3</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>65 and over</td>
<td>88.6</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

Rates are based on End Results data from a series of hospital registries and one population-based registry.
Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.
The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).
The standard error of the survival rate is greater than 5 and 10 percentage points.
The standard error of the survival rate is greater than 5 percentage points.
In situ cases are not included in the All Stages group.
Statistic could not be calculated.
Table V-4  
CERVIX UTERI CANCER (Invasive)  
SURVIVAL RATES, BY RACE, DIAGNOSIS YEAR, STAGE AND AGE

<table>
<thead>
<tr>
<th>YEAR OF DIAGNOSIS</th>
<th>All Races, Females</th>
<th>White Females</th>
<th>Black Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>5-YR RELATIVE SURVIVAL RATES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL</td>
<td>&lt;50</td>
<td>50+</td>
<td>All</td>
</tr>
<tr>
<td>1960-1963&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-</td>
<td>-</td>
<td>58</td>
</tr>
<tr>
<td>1970-1973&lt;sup&gt;a&lt;/sup&gt;</td>
<td>-</td>
<td>-</td>
<td>64</td>
</tr>
<tr>
<td>1974-1976&lt;sup&gt;b&lt;/sup&gt;</td>
<td>69.2</td>
<td>81.5</td>
<td>58.2</td>
</tr>
<tr>
<td>1977-1979&lt;sup&gt;b&lt;/sup&gt;</td>
<td>68.6</td>
<td>78.3</td>
<td>59.7</td>
</tr>
<tr>
<td>1980-1982&lt;sup&gt;b&lt;/sup&gt;</td>
<td>67.7</td>
<td>79.4</td>
<td>56.2</td>
</tr>
<tr>
<td>1983-1985&lt;sup&gt;b&lt;/sup&gt;</td>
<td>68.9</td>
<td>78.5</td>
<td>57.9</td>
</tr>
<tr>
<td>1986-1988&lt;sup&gt;b&lt;/sup&gt;</td>
<td>69.1</td>
<td>78.8</td>
<td>56.7</td>
</tr>
<tr>
<td>1989-1991&lt;sup&gt;b&lt;/sup&gt;</td>
<td>71.1</td>
<td>78.5</td>
<td>60.8</td>
</tr>
<tr>
<td>1992-1994&lt;sup&gt;b&lt;/sup&gt;</td>
<td>70.7</td>
<td>80.1</td>
<td>57.0</td>
</tr>
<tr>
<td>1995-2000&lt;sup&gt;b&lt;/sup&gt;</td>
<td>72.7&lt;sup&gt;c&lt;/sup&gt;</td>
<td>80.7</td>
<td>60.8</td>
</tr>
</tbody>
</table>

1995-2000<sup>b</sup>

<table>
<thead>
<tr>
<th>STAGE DISTRIBUTION (%) 1995-2000&lt;sup&gt;b&lt;/sup&gt;</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL STAGES</td>
<td>Number of cases</td>
<td>6,321</td>
<td>3,687</td>
</tr>
<tr>
<td>Percent</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>LOCALIZED</td>
<td>55</td>
<td>66</td>
<td>40</td>
</tr>
<tr>
<td>REGIONAL</td>
<td>32</td>
<td>24</td>
<td>42</td>
</tr>
<tr>
<td>DISTANT</td>
<td>7</td>
<td>5</td>
<td>11</td>
</tr>
<tr>
<td>UNSTAGED</td>
<td>6</td>
<td>5</td>
<td>8</td>
</tr>
</tbody>
</table>

1995-2000<sup>b</sup>

5-YR RELATIVE SURVIVAL RATES, 1995-2000<sup>b</sup>

<table>
<thead>
<tr>
<th>AGE AT DIAGNOSIS</th>
<th>All</th>
<th>&lt;50</th>
<th>50+</th>
<th>All</th>
<th>&lt;50</th>
<th>50+</th>
<th>All</th>
<th>&lt;50</th>
<th>50+</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;45</td>
<td>82.4</td>
<td>-</td>
<td>-</td>
<td>84.1</td>
<td>-</td>
<td>-</td>
<td>71.6</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>45-54</td>
<td>70.7</td>
<td>-</td>
<td>-</td>
<td>72.4</td>
<td>-</td>
<td>-</td>
<td>58.6</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>55-64</td>
<td>64.3</td>
<td>-</td>
<td>-</td>
<td>61.8</td>
<td>-</td>
<td>-</td>
<td>63.4&lt;sup&gt;d&lt;/sup&gt;</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>65-74</td>
<td>64.4</td>
<td>-</td>
<td>-</td>
<td>64.9</td>
<td>-</td>
<td>-</td>
<td>63.8&lt;sup&gt;d&lt;/sup&gt;</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>75+</td>
<td>43.5</td>
<td>-</td>
<td>-</td>
<td>39.9</td>
<td>-</td>
<td>-</td>
<td>60.4&lt;sup&gt;d&lt;/sup&gt;</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Under 65</td>
<td>76.3</td>
<td>-</td>
<td>-</td>
<td>77.7</td>
<td>-</td>
<td>-</td>
<td>66.8</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>65 and over</td>
<td>55.7</td>
<td>-</td>
<td>-</td>
<td>54.8</td>
<td>-</td>
<td>-</td>
<td>62.0&lt;sup&gt;d&lt;/sup&gt;</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

---

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

<sup>c</sup> The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).

<sup>d</sup> The standard error of the survival rate is greater than 10 percentage points.

<sup>e</sup> Statistic could not be calculated.
# Table VI-7

### Colon and Rectum Cancer (Invasive)

#### Survival Rates, by Race, Sex, Diagnosis Year, Stage and Age

<table>
<thead>
<tr>
<th>Year of Diagnosis</th>
<th>All Races</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1960-1963</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1970-1973</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1974-1976</td>
<td>49.8</td>
<td>48.8</td>
<td>50.7</td>
</tr>
<tr>
<td>1977-1979</td>
<td>52.0</td>
<td>50.8</td>
<td>53.1</td>
</tr>
<tr>
<td>1980-1982</td>
<td>54.4</td>
<td>53.9</td>
<td>54.9</td>
</tr>
<tr>
<td>1983-1985</td>
<td>56.9</td>
<td>56.9</td>
<td>57.0</td>
</tr>
<tr>
<td>1986-1988</td>
<td>60.2</td>
<td>60.5</td>
<td>60.0</td>
</tr>
<tr>
<td>1989-1991</td>
<td>61.8</td>
<td>62.0</td>
<td>61.7</td>
</tr>
<tr>
<td>1992-1994</td>
<td>61.8</td>
<td>61.7</td>
<td>61.9</td>
</tr>
<tr>
<td>1995-2000</td>
<td>63.4</td>
<td>63.7</td>
<td>63.1</td>
</tr>
</tbody>
</table>

**Stage Distribution (%) 1995-2000**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Number of cases</th>
<th>All Stages</th>
<th>Localized</th>
<th>Regional</th>
<th>Distinct</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>63,334</td>
<td>31,787</td>
<td>31,547</td>
<td>52,500</td>
<td>26,401</td>
<td>26,099</td>
</tr>
</tbody>
</table>

**5-Year Relative Survival Rates, 1995-2000**

<table>
<thead>
<tr>
<th>Age at Diagnosis</th>
<th>All Races</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;45</td>
<td>61.9</td>
<td>62.1</td>
<td>61.7</td>
</tr>
<tr>
<td>45-54</td>
<td>65.5</td>
<td>64.9</td>
<td>66.2</td>
</tr>
<tr>
<td>55-64</td>
<td>65.4</td>
<td>65.2</td>
<td>65.6</td>
</tr>
<tr>
<td>65-74</td>
<td>65.2</td>
<td>64.7</td>
<td>65.7</td>
</tr>
<tr>
<td>75+</td>
<td>59.9</td>
<td>61.4</td>
<td>59.1</td>
</tr>
<tr>
<td>Under 65</td>
<td>64.8</td>
<td>64.6</td>
<td>65.2</td>
</tr>
<tr>
<td>65 and over</td>
<td>62.7</td>
<td>63.4</td>
<td>62.1</td>
</tr>
</tbody>
</table>

---

* Rates are based on End Results data from a series of hospital registries and one population-based registry.

** Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

---

The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).

The standard error of the survival rate is greater than 10 percentage points.

Statistic could not be calculated.
### SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

#### 5-YR RELATIVE SURVIVAL RATES

**YEAR OF DIAGNOSIS:**

<table>
<thead>
<tr>
<th>Year</th>
<th>All Races</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
</tbody>
</table>

#### STAGE DISTRIBUTION (%) 1995-2000

<table>
<thead>
<tr>
<th>Stage</th>
<th>Number of cases</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Localized</td>
<td>34.9%</td>
<td></td>
</tr>
<tr>
<td>Regional</td>
<td>52.6%</td>
<td></td>
</tr>
<tr>
<td>Distant</td>
<td>11.8%</td>
<td></td>
</tr>
<tr>
<td>Unstaged</td>
<td>1.7%</td>
<td></td>
</tr>
</tbody>
</table>

#### 5-YR RELATIVE SURVIVAL RATES, 1995-2000

**AGE AT DIAGNOSIS:**

- <45
- 45-54
- 55-64
- 65-74
- 75+
- Under 65
- 65 and over

**Note:** Rates are based on follow-up of patients into 2001. The standard error of the survival rate is greater than 10 percentage points.
<table>
<thead>
<tr>
<th>AGE AT DIAGNOSIS</th>
<th>Whites</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td></td>
</tr>
<tr>
<td>&lt;45</td>
<td>62.4</td>
<td>59.9</td>
<td>65.3</td>
<td>63.6</td>
<td>61.4</td>
<td>66.2</td>
<td>53.6</td>
<td>52.4</td>
<td>52.9</td>
<td></td>
</tr>
<tr>
<td>45-54</td>
<td>69.2</td>
<td>66.8</td>
<td>73.1</td>
<td>70.8</td>
<td>68.0</td>
<td>75.2</td>
<td>62.2</td>
<td>63.8</td>
<td>59.5</td>
<td></td>
</tr>
<tr>
<td>55-64</td>
<td>66.6</td>
<td>65.2</td>
<td>68.8</td>
<td>66.4</td>
<td>65.2</td>
<td>68.1</td>
<td>62.3</td>
<td>56.2</td>
<td>70.5</td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td>66.4</td>
<td>64.3</td>
<td>69.5</td>
<td>66.4</td>
<td>63.9</td>
<td>70.0</td>
<td>52.0</td>
<td>48.7</td>
<td>55.2</td>
<td></td>
</tr>
<tr>
<td>75+</td>
<td>57.1</td>
<td>58.0</td>
<td>56.6</td>
<td>58.1</td>
<td>59.5</td>
<td>57.2</td>
<td>43.2</td>
<td>36.9</td>
<td>46.3</td>
<td></td>
</tr>
<tr>
<td>Under 65</td>
<td>66.8</td>
<td>64.9</td>
<td>69.6</td>
<td>67.3</td>
<td>65.5</td>
<td>70.0</td>
<td>60.5</td>
<td>58.4</td>
<td>63.7</td>
<td></td>
</tr>
<tr>
<td>65 and over</td>
<td>62.4</td>
<td>61.9</td>
<td>62.9</td>
<td>62.8</td>
<td>62.2</td>
<td>63.4</td>
<td>48.1</td>
<td>44.6</td>
<td>50.7</td>
<td></td>
</tr>
</tbody>
</table>

Rates are based on End Results data from a series of hospital registries and one population-based registry.

a Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

b The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).

c The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated.
### Table VII-4
CORPUS AND UTERUS, NOS CANCER (Invasive)

**SURVIVAL RATES, BY RACE, DIAGNOSIS YEAR, STAGE AND AGE**

<table>
<thead>
<tr>
<th>All Races, Females</th>
<th>White Females</th>
<th>Black Females</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;50</td>
<td>50+</td>
</tr>
<tr>
<td><strong>5-YR RELATIVE SURVIVAL RATES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YEAR OF DIAGNOSIS:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1960-1963a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1970-1973a</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1974-1976a</td>
<td>88.0</td>
<td>92.2</td>
</tr>
<tr>
<td>1977-1979b</td>
<td>85.1</td>
<td>92.2</td>
</tr>
<tr>
<td>1980-1982b</td>
<td>81.6</td>
<td>91.2</td>
</tr>
<tr>
<td>1983-1985b</td>
<td>82.9</td>
<td>92.6</td>
</tr>
<tr>
<td>1986-1988b</td>
<td>82.9</td>
<td>92.5</td>
</tr>
<tr>
<td>1989-1991b</td>
<td>83.8</td>
<td>88.5</td>
</tr>
<tr>
<td>1992-1994b</td>
<td>84.3</td>
<td>90.2</td>
</tr>
<tr>
<td>1995-2000b</td>
<td>84.4c</td>
<td>89.6c</td>
</tr>
</tbody>
</table>

| 1995-2000b |     |     |     |     |     |     |
| ALL STAGES | 84.4 | 89.6 | 83.5 | 86.1 | 90.7 | 85.4 | 63.1 | 81.1 | 59.2 |
| LOCALIZED | 95.8 | 96.3 | 95.8 | 96.6 | 97.0 | 96.6 | 85.2 | 92.2 | 83.4 |
| REGIONAL | 67.0 | 82.1 | 64.2 | 69.6 | 84.3 | 67.0 | 43.5 | 64.2d | 39.6 |
| DISTANT | 25.6 | 38.0 | 23.6 | 27.5 | 38.5d | 25.7 | 16.8 | 7.8 | 15.3 |
| UNSTAGED | 56.3 | 82.9d | 52.2 | 56.6 | 89.0 | 52.4 | 52.6d | 47.9d | 47.9d |

<table>
<thead>
<tr>
<th>STAGE DISTRIBUTION (%) 1995-2000b</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>ALL STAGES</strong></td>
</tr>
<tr>
<td>Percent</td>
</tr>
<tr>
<td>LOCALIZED</td>
</tr>
<tr>
<td>REGIONAL</td>
</tr>
<tr>
<td>DISTANT</td>
</tr>
<tr>
<td>UNSTAGED</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>5-YR RELATIVE SURVIVAL RATES, 1995-2000b</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AGE AT DIAGNOSIS:</strong></td>
</tr>
<tr>
<td>&lt;45</td>
</tr>
<tr>
<td>45-54</td>
</tr>
<tr>
<td>55-64</td>
</tr>
<tr>
<td>65-74</td>
</tr>
<tr>
<td>75+</td>
</tr>
<tr>
<td>Under 65</td>
</tr>
<tr>
<td>65 and over</td>
</tr>
</tbody>
</table>

---

Reported rates are the survival proportions of patients alive at the end of the period specified. Rates are based on follow-up of patients into 2001.

Note: The standard error of the survival rates is greater than 0.5 percentage points.

---

**Notes:**
- Rates are based on SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.
- The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).
- The standard error of the survival rate is greater than 10 percentage points.
- Statistic could not be calculated.
## 5-YR RELATIVE SURVIVAL RATES

### YEAR OF DIAGNOSIS:

<table>
<thead>
<tr>
<th>All Races</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td>1960-1963</td>
<td>- - -</td>
<td>4 4 6</td>
</tr>
<tr>
<td>1970-1973</td>
<td>- - -</td>
<td>4 4 4</td>
</tr>
<tr>
<td>1974-1976</td>
<td>4.8 3.8 7.3</td>
<td>5.3 4.6 6.8</td>
</tr>
<tr>
<td>1977-1979</td>
<td>5.1 4.9 5.8</td>
<td>5.7 5.8 5.6</td>
</tr>
<tr>
<td>1980-1982</td>
<td>6.7 6.0 8.5</td>
<td>7.3 6.4 9.2</td>
</tr>
<tr>
<td>1983-1985</td>
<td>8.2 6.8 11.8</td>
<td>9.3 7.7 13.2</td>
</tr>
<tr>
<td>1986-1988</td>
<td>9.8 9.9 9.4</td>
<td>10.7 11.3 9.4</td>
</tr>
<tr>
<td>1989-1991</td>
<td>11.0 10.8 11.4</td>
<td>11.7 11.8 11.5</td>
</tr>
<tr>
<td>1995-2000</td>
<td>14.3 14.2 14.7</td>
<td>15.8 15.6 16.3</td>
</tr>
</tbody>
</table>

### STAGE DISTRIBUTION (%): 1995-2000

<table>
<thead>
<tr>
<th>All Stages</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cases</td>
<td>5,485</td>
<td>4,148</td>
<td>1,337</td>
</tr>
<tr>
<td>Percent</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Localized</td>
<td>29.3</td>
<td>26</td>
<td>27.1</td>
</tr>
<tr>
<td>Regional</td>
<td>13.3</td>
<td>12.0</td>
<td>17.1</td>
</tr>
<tr>
<td>Distant</td>
<td>3.1</td>
<td>3.0</td>
<td>3.3</td>
</tr>
<tr>
<td>Unstaged</td>
<td>11.3</td>
<td>12.9</td>
<td>8.1</td>
</tr>
</tbody>
</table>

### 5-YR RELATIVE SURVIVAL RATES, 1995-2000

### AGE AT DIAGNOSIS:

<table>
<thead>
<tr>
<th>Age</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;45</td>
<td>22.5</td>
<td>20.6</td>
<td>30.2</td>
</tr>
<tr>
<td>45-54</td>
<td>15.2</td>
<td>15.6</td>
<td>13.1</td>
</tr>
<tr>
<td>55-64</td>
<td>16.8</td>
<td>16.5</td>
<td>18.1</td>
</tr>
<tr>
<td>65-74</td>
<td>14.2</td>
<td>13.6</td>
<td>16.2</td>
</tr>
<tr>
<td>75+</td>
<td>8.9</td>
<td>8.1</td>
<td>10.1</td>
</tr>
<tr>
<td>Under 65</td>
<td>16.7</td>
<td>16.4</td>
<td>18.1</td>
</tr>
<tr>
<td>65 and over</td>
<td>12.3</td>
<td>11.8</td>
<td>13.2</td>
</tr>
</tbody>
</table>

Rates are based on End Results data from a series of hospital registries and one population-based registry.

Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).

The standard error of the survival rate is greater than 10 percentage points.
Table IX-4
HODGKIN LYMPHOMA

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR AND AGE

<table>
<thead>
<tr>
<th>5-YR RELATIVE SURVIVAL RATES</th>
<th>All Races</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td><strong>YEAR OF DIAGNOSIS:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1960-1963*</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1970-1973*</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1974-1976*</td>
<td>71.2</td>
<td>69.7</td>
<td>73.1</td>
</tr>
<tr>
<td>1977-1979*</td>
<td>73.2</td>
<td>70.9</td>
<td>76.2</td>
</tr>
<tr>
<td>1980-1982*</td>
<td>74.5</td>
<td>74.0</td>
<td>75.2</td>
</tr>
<tr>
<td>1983-1985*</td>
<td>78.8</td>
<td>77.6</td>
<td>80.4</td>
</tr>
<tr>
<td>1986-1988*</td>
<td>79.4</td>
<td>77.0</td>
<td>82.3</td>
</tr>
<tr>
<td>1989-1991*</td>
<td>81.4</td>
<td>78.9</td>
<td>84.5</td>
</tr>
<tr>
<td>1992-1994*</td>
<td>83.4</td>
<td>80.7</td>
<td>86.5</td>
</tr>
<tr>
<td>1995-2000*</td>
<td>85.2c</td>
<td>83.9d</td>
<td>86.8e</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>5-YR RELATIVE SURVIVAL RATES, 1995-2000</strong></th>
<th>All Races</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>AGE AT DIAGNOSIS:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;45</td>
<td>91.3</td>
<td>89.7</td>
<td>93.0</td>
</tr>
<tr>
<td>45-54</td>
<td>83.8</td>
<td>78.9</td>
<td>90.9</td>
</tr>
<tr>
<td>55-64</td>
<td>72.3</td>
<td>70.4</td>
<td>76.0</td>
</tr>
<tr>
<td>65-74</td>
<td>59.9</td>
<td>58.9d</td>
<td>60.0d</td>
</tr>
<tr>
<td>75+</td>
<td>44.1d</td>
<td>52.8d</td>
<td>33.8d</td>
</tr>
<tr>
<td>Under 65</td>
<td>88.8</td>
<td>86.4</td>
<td>91.7</td>
</tr>
<tr>
<td>65 and over</td>
<td>52.8</td>
<td>57.8d</td>
<td>48.4</td>
</tr>
</tbody>
</table>

* Rates are based on End Results data from a series of hospital registries and one population-based registry.

b Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

c The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).

d The standard error of the survival rate is between 5 and 10 percentage points.

e The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated.
### Table XI-4

**KIDNEY AND RENAL PELVIS CANCER (Invasive)**

**SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE**

<table>
<thead>
<tr>
<th></th>
<th>All Races</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td>Total</td>
</tr>
<tr>
<td><strong>YEAR OF DIAGNOSIS:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1960-1963*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1970-1973*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1974-1976*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1977-1979*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1980-1982*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1983-1985*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1986-1988*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1989-1991*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1992-1994*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1995-2000b</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**STAGE DISTRIBUTION (%) 1995-2000b**

<table>
<thead>
<tr>
<th></th>
<th>All Stages</th>
<th>Localized</th>
<th>Regional</th>
<th>Distant</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cases</td>
<td>13,092</td>
<td>8,008</td>
<td>5,084</td>
<td>10,933</td>
<td>6,745</td>
</tr>
<tr>
<td>Percent</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Localized</td>
<td>52</td>
<td>51</td>
<td>54</td>
<td>52</td>
<td>51</td>
</tr>
<tr>
<td>Regional</td>
<td>21</td>
<td>22</td>
<td>19</td>
<td>21</td>
<td>22</td>
</tr>
<tr>
<td>Distant</td>
<td>22</td>
<td>22</td>
<td>21</td>
<td>22</td>
<td>22</td>
</tr>
<tr>
<td>Unstaged</td>
<td>6</td>
<td>5</td>
<td>7</td>
<td>6</td>
<td>5</td>
</tr>
</tbody>
</table>

**5-YR RELATIVE SURVIVAL RATES, 1995-2000b**

<table>
<thead>
<tr>
<th>Age at Diagnosis</th>
<th>All Races</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>&lt;45</td>
<td>80.2</td>
<td>79.2</td>
<td>81.7</td>
</tr>
<tr>
<td>45-54</td>
<td>68.8</td>
<td>65.2</td>
<td>77.0</td>
</tr>
<tr>
<td>55-64</td>
<td>62.1</td>
<td>61.6</td>
<td>63.2</td>
</tr>
<tr>
<td>65-74</td>
<td>61.8</td>
<td>62.1</td>
<td>61.5</td>
</tr>
<tr>
<td>75+</td>
<td>52.0</td>
<td>56.2</td>
<td>47.7</td>
</tr>
<tr>
<td>Under 65</td>
<td>68.5</td>
<td>66.5</td>
<td>72.5</td>
</tr>
<tr>
<td>65 and over</td>
<td>58.0</td>
<td>60.2</td>
<td>55.4</td>
</tr>
</tbody>
</table>

* Rates are based on End Results data from a series of hospital registries and one population-based registry.

b Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

c The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).

d The standard error of the survival rate is less than 10 percentage points.

- Statistic could not be calculated.
Table XII-4
LARYNX CANCER (Invasive)
SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

<table>
<thead>
<tr>
<th>YEAR OF DIAGNOSIS</th>
<th>TOTAL</th>
<th>MALES</th>
<th>FEMALES</th>
<th>TOTAL</th>
<th>MALES</th>
<th>FEMALES</th>
<th>TOTAL</th>
<th>MALES</th>
<th>FEMALES</th>
</tr>
</thead>
<tbody>
<tr>
<td>1960-1963*</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>53</td>
<td>54</td>
<td>46</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1970-1973*</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>62</td>
<td>63</td>
<td>56</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1974-1976*</td>
<td>65.7</td>
<td>65.4</td>
<td>67.2</td>
<td>66.4</td>
<td>66.1</td>
<td>67.9</td>
<td>59.9</td>
<td>59.1</td>
<td>64.0d</td>
</tr>
<tr>
<td>1977-1979*</td>
<td>67.0</td>
<td>67.9</td>
<td>62.8</td>
<td>68.3</td>
<td>69.4</td>
<td>62.6</td>
<td>55.8</td>
<td>54.0</td>
<td>63.0d</td>
</tr>
<tr>
<td>1980-1982b</td>
<td>68.1</td>
<td>68.0</td>
<td>68.5</td>
<td>69.3</td>
<td>69.0</td>
<td>70.4</td>
<td>58.3</td>
<td>59.7</td>
<td>56.1d</td>
</tr>
<tr>
<td>1983-1985b</td>
<td>67.1</td>
<td>68.3</td>
<td>61.9</td>
<td>68.6</td>
<td>69.6</td>
<td>63.7</td>
<td>55.3</td>
<td>56.5</td>
<td>51.3d</td>
</tr>
<tr>
<td>1986-1988b</td>
<td>66.7</td>
<td>67.4</td>
<td>64.2</td>
<td>68.7</td>
<td>69.8</td>
<td>64.2</td>
<td>54.1</td>
<td>52.3</td>
<td>61.5d</td>
</tr>
<tr>
<td>1989-1991b</td>
<td>65.6</td>
<td>66.9</td>
<td>61.0</td>
<td>66.7</td>
<td>68.0</td>
<td>61.9</td>
<td>55.9</td>
<td>56.1</td>
<td>55.2d</td>
</tr>
<tr>
<td>1992-1994b</td>
<td>64.2</td>
<td>65.7</td>
<td>58.6</td>
<td>66.2</td>
<td>67.5</td>
<td>60.7</td>
<td>53.8</td>
<td>55.7</td>
<td>46.6d</td>
</tr>
<tr>
<td>1995-2000b</td>
<td>65.1</td>
<td>66.7</td>
<td>59.6</td>
<td>67.4</td>
<td>68.9</td>
<td>62.0</td>
<td>51.0</td>
<td>52.5</td>
<td>46.5d</td>
</tr>
</tbody>
</table>

1995-2000b
ALL STAGES
| PERCENT | 65.1 | 66.7 | 59.6 | 67.4 | 68.9 | 62.0 | 51.0 | 52.5 | 46.5d |
| LOCALIZED | 83.7 | 85.6 | 76.3 | 85.9 | 87.9 | 78.0 | 67.7 | 70.2d | 60.0d |
| REGIONAL | 48.7 | 48.9 | 48.0 | 49.9 | 50.2 | 49.2 | 42.7 | 42.3 | 43.6d |
| DISTANT | 18.7 | 20.5 | 9.5d | 16.9 | 19.6 | - | 19.4d | 0.0 | - |
| UNSTAGED | 55.6 | 60.3d | 45.2d | 58.9d | 61.3d | 53.7d | - | - | - |

STAGE DISTRIBUTION (%), 1995-2000b
ALL STAGES
| PERCENT | 4,937 | 3,884 | 1,053 | 4,025 | 3,184 | 841 | 693 | 520 | 173 |
| LOCALIZED | 49 | 50 | 44 | 50 | 52 | 46 | 38 | 39 | 34 |
| REGIONAL | 44 | 43 | 47 | 42 | 41 | 46 | 53 | 53 | 54 |
| DISTANT | 4 | 4 | 3 | 4 | 4 | 4 | 6 | 6 | 5 |
| UNSTAGED | 4 | 3 | 5 | 4 | 4 | 5 | 3 | 2 | 7 |

5-YR RELATIVE SURVIVAL RATES, 1995-2000b
AGE AT DIAGNOSIS:
<table>
<thead>
<tr>
<th>AGE</th>
<th>All Races</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;45</td>
<td>69.1</td>
<td>67.5</td>
<td>72.0d</td>
</tr>
<tr>
<td>45-54</td>
<td>68.1</td>
<td>69.0</td>
<td>63.6d</td>
</tr>
<tr>
<td>55-64</td>
<td>64.6</td>
<td>65.2</td>
<td>62.4</td>
</tr>
<tr>
<td>65-74</td>
<td>65.5</td>
<td>68.5</td>
<td>55.1</td>
</tr>
<tr>
<td>75+</td>
<td>60.5</td>
<td>63.4</td>
<td>52.8d</td>
</tr>
<tr>
<td>Under 65</td>
<td>66.3</td>
<td>66.8</td>
<td>64.3</td>
</tr>
<tr>
<td>65 and over</td>
<td>64.0</td>
<td>67.0</td>
<td>54.4</td>
</tr>
</tbody>
</table>

Rates are based on End Results data from a series of hospital registries and one population-based registry.
Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.
The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).
The standard error of the survival rate is greater than 10 percentage points.
Statistic could not be calculated.
**Table XIII-8**

**LEUKEMIA**

**SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR AND AGE**

<table>
<thead>
<tr>
<th></th>
<th>All Races</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td>Total</td>
</tr>
<tr>
<td><strong>5-YR RELATIVE SURVIVAL RATES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>YEAR OF DIAGNOSIS:</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1960-1963*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1970-1973*</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1974-1976*</td>
<td>34.4</td>
<td>33.2</td>
<td>36.0</td>
<td>35.2</td>
</tr>
<tr>
<td>1977-1979*</td>
<td>37.3</td>
<td>36.5</td>
<td>38.2</td>
<td>38.1</td>
</tr>
<tr>
<td>1980-1982*</td>
<td>38.7</td>
<td>38.4</td>
<td>39.1</td>
<td>39.5</td>
</tr>
<tr>
<td>1983-1985*</td>
<td>40.8</td>
<td>40.3</td>
<td>41.5</td>
<td>42.1</td>
</tr>
<tr>
<td>1986-1988*</td>
<td>43.2</td>
<td>44.3</td>
<td>41.8</td>
<td>44.3</td>
</tr>
<tr>
<td>1989-1991*</td>
<td>45.1</td>
<td>44.9</td>
<td>45.4</td>
<td>46.4</td>
</tr>
<tr>
<td>1992-1994*</td>
<td>47.6</td>
<td>48.7</td>
<td>46.1</td>
<td>49.2</td>
</tr>
<tr>
<td>1995-2000*</td>
<td>46.4c</td>
<td>47.0c</td>
<td>45.7c</td>
<td>47.8c</td>
</tr>
</tbody>
</table>

| **5-YR RELATIVE SURVIVAL RATES, 1995-2000** |           |       |         |       |       |         |       |       |         |
| **AGE AT DIAGNOSIS:** |           |       |         |       |       |         |       |       |         |
| <45                  | 62.5      | 61.9  | 63.3    | 64.6  | 63.9  | 65.6    | 50.0  | 48.9  | 51.5    |
| 45-54                | 55.0      | 57.2  | 51.6    | 57.2  | 58.4  | 55.3    | 44.6d | 47.7d | 40.2d   |
| 55-64                | 49.3      | 49.8  | 48.6    | 51.9  | 52.3  | 51.2    | 33.7d | 31.2d | 36.6d   |
| 65-74                | 39.8      | 38.4  | 41.7    | 41.9  | 40.3  | 44.3    | 27.1  | 27.2d | 27.9d   |
| 75+                  | 27.7      | 26.1  | 29.0    | 28.8  | 26.8  | 30.4    | 22.5  | 23.2d | 22.2d   |
| Under 65             | 57.1      | 57.4  | 56.7    | 59.1  | 59.1  | 59.2    | 45.6  | 45.4  | 45.7    |
| 65 and over          | 33.9      | 33.2  | 34.6    | 35.5  | 34.5  | 36.5    | 25.1  | 25.8  | 25.1    |

* Rates are based on End Results data from a series of hospital registries and one population-based registry.

b Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

c The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).

d The standard error of the survival rate is between 5 and 10 percentage points.

e The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated.
ACUTE LYMPHOCYTIC LEUKEMIA
5-YR RELATIVE SURVIVAL RATES

YEAR OF DIAGNOSIS:

<table>
<thead>
<tr>
<th>Year</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>1974-1976a</td>
<td>38.3</td>
<td>34.3</td>
<td>43.9</td>
</tr>
<tr>
<td>1977-1979a</td>
<td>51.0</td>
<td>47.6</td>
<td>55.8</td>
</tr>
<tr>
<td>1980-1982a</td>
<td>53.2</td>
<td>49.5</td>
<td>58.2</td>
</tr>
<tr>
<td>1983-1985a</td>
<td>51.3</td>
<td>48.1</td>
<td>55.4</td>
</tr>
<tr>
<td>1986-1988a</td>
<td>55.2</td>
<td>53.7</td>
<td>57.5</td>
</tr>
<tr>
<td>1989-1991a</td>
<td>58.9</td>
<td>57.4</td>
<td>60.9</td>
</tr>
<tr>
<td>1992-1994b</td>
<td>60.2</td>
<td>56.7</td>
<td>64.7</td>
</tr>
<tr>
<td>1995-2000b</td>
<td>64.8b</td>
<td>64.6b</td>
<td>65.2b</td>
</tr>
</tbody>
</table>

ACUTE LYMPHOCYTIC LEUKEMIA
5-YR RELATIVE SURVIVAL RATES, 1995-2000a

AGE AT DIAGNOSIS:

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;45</td>
<td>74.4</td>
<td>73.1</td>
<td>76.3</td>
</tr>
<tr>
<td>45-54</td>
<td>29.6</td>
<td>28.9c</td>
<td>31.2c</td>
</tr>
<tr>
<td>55-64</td>
<td>18.7c</td>
<td>21.2c</td>
<td>14.5c</td>
</tr>
<tr>
<td>65-74</td>
<td>8.7c</td>
<td>7.1c</td>
<td>10.8c</td>
</tr>
<tr>
<td>75+</td>
<td>5.8c</td>
<td>3.9c</td>
<td></td>
</tr>
<tr>
<td>Under 65</td>
<td>69.1</td>
<td>68.0c</td>
<td>70.6</td>
</tr>
<tr>
<td>65 and over</td>
<td>7.6</td>
<td>6.5c</td>
<td>8.6</td>
</tr>
</tbody>
</table>

CHRONIC LYMPHOCYTIC LEUKEMIA
5-YR RELATIVE SURVIVAL RATES

YEAR OF DIAGNOSIS:

<table>
<thead>
<tr>
<th>Year</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>1974-1976a</td>
<td>68.2</td>
<td>65.6</td>
<td>71.7</td>
</tr>
<tr>
<td>1977-1979a</td>
<td>70.1</td>
<td>68.4</td>
<td>72.3</td>
</tr>
<tr>
<td>1980-1982a</td>
<td>68.4</td>
<td>67.8</td>
<td>69.4</td>
</tr>
<tr>
<td>1983-1985a</td>
<td>73.6</td>
<td>72.1</td>
<td>75.6</td>
</tr>
<tr>
<td>1986-1988a</td>
<td>73.4</td>
<td>72.3</td>
<td>75.1</td>
</tr>
<tr>
<td>1989-1991a</td>
<td>73.5</td>
<td>72.5</td>
<td>74.8</td>
</tr>
<tr>
<td>1992-1994a</td>
<td>76.0</td>
<td>77.1</td>
<td>74.5</td>
</tr>
<tr>
<td>1995-2000a</td>
<td>72.7b</td>
<td>70.6b</td>
<td>75.6</td>
</tr>
</tbody>
</table>

CHRONIC LYMPHOCYTIC LEUKEMIA
5-YR RELATIVE SURVIVAL RATES, 1995-2000a

AGE AT DIAGNOSIS:

<table>
<thead>
<tr>
<th>Age Group</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;45</td>
<td>81.3</td>
<td>82.1</td>
<td>79.6c</td>
</tr>
<tr>
<td>45-54</td>
<td>83.4</td>
<td>82.9</td>
<td>84.1</td>
</tr>
<tr>
<td>55-64</td>
<td>80.9</td>
<td>76.2</td>
<td>89.9</td>
</tr>
<tr>
<td>65-74</td>
<td>75.4</td>
<td>71.3</td>
<td>81.4</td>
</tr>
<tr>
<td>75+</td>
<td>58.6</td>
<td>54.6</td>
<td>61.9</td>
</tr>
<tr>
<td>Under 65</td>
<td>81.8</td>
<td>79.2</td>
<td>87.1</td>
</tr>
<tr>
<td>65 and over</td>
<td>67.7</td>
<td>64.7</td>
<td>71.0</td>
</tr>
</tbody>
</table>

Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).

The standard error of the survival rate is between 5 and 10 percentage points.

The standard error of the survival rate is greater than 10 percentage points.

Statistic could not be calculated.
**Table XIII-10**  
MYELOID LEUKEMIA  
SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR AND AGE  

<table>
<thead>
<tr>
<th>All Races</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
</tr>
<tr>
<td>5-yr Relative Survival Rates</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Year of Diagnosis:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1974-1976*</td>
<td>6.0</td>
<td>5.5</td>
</tr>
<tr>
<td>1977-1979*</td>
<td>8.4</td>
<td>7.5</td>
</tr>
<tr>
<td>1980-1982*</td>
<td>8.6</td>
<td>7.6</td>
</tr>
<tr>
<td>1983-1985*</td>
<td>11.4</td>
<td>10.8</td>
</tr>
<tr>
<td>1986-1988*</td>
<td>11.7</td>
<td>9.2</td>
</tr>
<tr>
<td>1989-1991*</td>
<td>13.8</td>
<td>11.9</td>
</tr>
<tr>
<td>1992-1994*</td>
<td>17.7</td>
<td>16.5</td>
</tr>
<tr>
<td>1995-2000*</td>
<td>19.5b</td>
<td>18.3b</td>
</tr>
</tbody>
</table>

**Acute Myeloid Leukemia**  
5-yr Relative Survival Rates, 1995-2000*  
Age at Diagnosis:  

<table>
<thead>
<tr>
<th></th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;45</td>
<td>44.9</td>
<td>43.4</td>
</tr>
<tr>
<td>45-54</td>
<td>26.5</td>
<td>26.3</td>
</tr>
<tr>
<td>55-64</td>
<td>16.9</td>
<td>14.1</td>
</tr>
<tr>
<td>65-74</td>
<td>5.3</td>
<td>3.8</td>
</tr>
<tr>
<td>75+</td>
<td>2.3</td>
<td>1.2</td>
</tr>
<tr>
<td>Under 65</td>
<td>32.7</td>
<td>31.2</td>
</tr>
<tr>
<td>65 and over</td>
<td>3.8</td>
<td>2.7</td>
</tr>
</tbody>
</table>

**Chronic Myeloid Leukemia**  
5-yr Relative Survival Rates, 1995-2000*  
Age at Diagnosis:  

<table>
<thead>
<tr>
<th></th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;45</td>
<td>56.8</td>
<td>53.1</td>
</tr>
<tr>
<td>45-54</td>
<td>54.3</td>
<td>49.5c</td>
</tr>
<tr>
<td>55-64</td>
<td>39.9</td>
<td>42.4c</td>
</tr>
<tr>
<td>65-74</td>
<td>23.7</td>
<td>25.0</td>
</tr>
<tr>
<td>75+</td>
<td>12.6</td>
<td>12.7</td>
</tr>
<tr>
<td>Under 65</td>
<td>51.1</td>
<td>49.0</td>
</tr>
<tr>
<td>65 and over</td>
<td>18.4</td>
<td>19.6</td>
</tr>
</tbody>
</table>

* Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.  
* The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).  
* The standard error of the survival rate is between 5 and 10 percentage points.  
* The standard error of the survival rate is greater than 10 percentage points.  
* Statistic could not be calculated.
### 5-YR RELATIVE SURVIVAL RATES

**YEAR OF DIAGNOSIS:**

<table>
<thead>
<tr>
<th>Year</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>1960-1963a</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1970-1973a</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1974-1976a</td>
<td>3.8</td>
<td>2.5</td>
<td>6.1</td>
</tr>
<tr>
<td>1977-1979b</td>
<td>3.7</td>
<td>2.1</td>
<td>6.6</td>
</tr>
<tr>
<td>1980-1982b</td>
<td>3.5</td>
<td>2.6</td>
<td>5.0</td>
</tr>
<tr>
<td>1983-1985b</td>
<td>5.6</td>
<td>4.0</td>
<td>8.8</td>
</tr>
<tr>
<td>1986-1988b</td>
<td>6.2</td>
<td>4.1</td>
<td>10.2</td>
</tr>
<tr>
<td>1989-1991b</td>
<td>5.2</td>
<td>4.0</td>
<td>7.3</td>
</tr>
<tr>
<td>1992-1994b</td>
<td>5.6</td>
<td>5.4</td>
<td>6.0</td>
</tr>
<tr>
<td>1995-2000b</td>
<td>8.3</td>
<td>7.7</td>
<td>9.6</td>
</tr>
</tbody>
</table>

**ALL STAGES**

<table>
<thead>
<tr>
<th>Year</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>1960-1963a</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1970-1973a</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1974-1976a</td>
<td>3.8</td>
<td>2.5</td>
<td>6.1</td>
</tr>
<tr>
<td>1977-1979b</td>
<td>3.7</td>
<td>2.1</td>
<td>6.6</td>
</tr>
<tr>
<td>1980-1982b</td>
<td>3.5</td>
<td>2.6</td>
<td>5.0</td>
</tr>
<tr>
<td>1983-1985b</td>
<td>5.6</td>
<td>4.0</td>
<td>8.8</td>
</tr>
<tr>
<td>1986-1988b</td>
<td>6.2</td>
<td>4.1</td>
<td>10.2</td>
</tr>
<tr>
<td>1989-1991b</td>
<td>5.2</td>
<td>4.0</td>
<td>7.3</td>
</tr>
<tr>
<td>1992-1994b</td>
<td>5.6</td>
<td>5.4</td>
<td>6.0</td>
</tr>
<tr>
<td>1995-2000b</td>
<td>8.3</td>
<td>7.7</td>
<td>9.6</td>
</tr>
</tbody>
</table>

**STAGE DISTRIBUTION (%) 1995-2000b**

<table>
<thead>
<tr>
<th>Stage</th>
<th>Total Cases</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Localized</td>
<td>6,457</td>
<td>4,356</td>
<td>2,101</td>
</tr>
<tr>
<td>Regional</td>
<td>4,252</td>
<td>2,829</td>
<td>1,423</td>
</tr>
<tr>
<td>Unstaged</td>
<td>4,252</td>
<td>2,829</td>
<td>1,423</td>
</tr>
<tr>
<td>Total</td>
<td>727</td>
<td>504</td>
<td>223</td>
</tr>
</tbody>
</table>

**5-YR RELATIVE SURVIVAL RATES, 1995-2000b**

<table>
<thead>
<tr>
<th>Age at Diagnosis</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;45</td>
<td>20.6</td>
<td>16.4</td>
<td>30.0</td>
</tr>
<tr>
<td>45-54</td>
<td>25.4</td>
<td>19.1</td>
<td>35.4d</td>
</tr>
<tr>
<td>55-64</td>
<td>8.0</td>
<td>7.7</td>
<td>8.9</td>
</tr>
<tr>
<td>65-74</td>
<td>7.3</td>
<td>6.9</td>
<td>8.0</td>
</tr>
<tr>
<td>75+</td>
<td>3.7</td>
<td>3.5</td>
<td>4.0</td>
</tr>
<tr>
<td>Under 65</td>
<td>11.0</td>
<td>9.4</td>
<td>15.9</td>
</tr>
<tr>
<td>65 and over</td>
<td>5.8</td>
<td>5.7</td>
<td>5.9</td>
</tr>
</tbody>
</table>

* Rates are based on End Results data from a series of hospital registries and one population-based registry.

b Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

c The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).
d The standard error of the survival rate is greater than 10 percentage points.
e The standard error of the survival rate is between 5 and 10 percentage points.
= Statistic could not be calculated.
Table XV-7
LUNG AND BRONCHUS CANCER (Invasive)

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

<table>
<thead>
<tr>
<th>5-YR RELATIVE SURVIVAL RATES</th>
<th>YEAR OF DIAGNOSIS:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>-</td>
</tr>
<tr>
<td>UNSTAGED</td>
<td>15.2&lt;sup&gt;c&lt;/sup&gt;</td>
</tr>
<tr>
<td>LOCALIZED</td>
<td>49.4</td>
</tr>
<tr>
<td>REGIONAL</td>
<td>19.1</td>
</tr>
<tr>
<td>DISTANT</td>
<td>2.1</td>
</tr>
<tr>
<td>UNSTAGED</td>
<td>8.2</td>
</tr>
</tbody>
</table>

STAGE DISTRIBUTION (%): 1995-2000<sup>b</sup>

<table>
<thead>
<tr>
<th>ALL STAGES</th>
<th>Number of cases</th>
<th>75,341</th>
<th>42,541</th>
<th>32,800</th>
<th>62,661</th>
<th>34,580</th>
<th>28,801</th>
<th>7,901</th>
<th>4,911</th>
<th>2,990</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percent</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>LOCALIZED</td>
<td>16</td>
<td>15</td>
<td>18</td>
<td>17</td>
<td>15</td>
<td>18</td>
<td>14</td>
<td>13</td>
<td>16</td>
<td></td>
</tr>
<tr>
<td>REGIONAL</td>
<td>37</td>
<td>38</td>
<td>36</td>
<td>37</td>
<td>37</td>
<td>36</td>
<td>38</td>
<td>37</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>DISTANT</td>
<td>39</td>
<td>40</td>
<td>38</td>
<td>39</td>
<td>40</td>
<td>38</td>
<td>40</td>
<td>42</td>
<td>38</td>
<td></td>
</tr>
<tr>
<td>UNSTAGED</td>
<td>8</td>
<td>8</td>
<td>9</td>
<td>8</td>
<td>8</td>
<td>9</td>
<td>8</td>
<td>8</td>
<td>8</td>
<td></td>
</tr>
</tbody>
</table>

5-YR RELATIVE SURVIVAL RATES, 1995-2000<sup>b</sup>

<table>
<thead>
<tr>
<th>AGE AT DIAGNOSIS:</th>
<th>&lt;45</th>
<th>45-54</th>
<th>55-64</th>
<th>65-74</th>
<th>75+</th>
<th>Under 65</th>
<th>65 and over</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>22.2</td>
<td>19.3</td>
<td>25.7</td>
<td>24.5</td>
<td>22.3</td>
<td>27.0</td>
<td>16.1</td>
</tr>
<tr>
<td></td>
<td>19.0</td>
<td>15.8</td>
<td>23.2</td>
<td>19.4</td>
<td>15.5</td>
<td>24.2</td>
<td>16.1</td>
</tr>
<tr>
<td></td>
<td>17.2</td>
<td>15.1</td>
<td>20.2</td>
<td>17.7</td>
<td>15.6</td>
<td>20.3</td>
<td>13.4</td>
</tr>
<tr>
<td></td>
<td>15.3</td>
<td>13.8</td>
<td>17.2</td>
<td>15.5</td>
<td>13.8</td>
<td>17.6</td>
<td>12.4</td>
</tr>
<tr>
<td></td>
<td>10.0</td>
<td>9.2</td>
<td>10.8</td>
<td>10.0</td>
<td>9.1</td>
<td>10.9</td>
<td>10.1</td>
</tr>
<tr>
<td></td>
<td>18.2</td>
<td>15.7</td>
<td>21.5</td>
<td>18.7</td>
<td>16.1</td>
<td>22.0</td>
<td>14.6</td>
</tr>
<tr>
<td></td>
<td>13.3</td>
<td>12.1</td>
<td>14.6</td>
<td>13.4</td>
<td>12.1</td>
<td>14.8</td>
<td>11.6</td>
</tr>
</tbody>
</table>

* Rates are based on End Results data from a series of hospital registries and one population-based registry.
* Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.
* The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).
* The standard error of the survival rate is greater than 10 percentage points.
* Statistic could not be calculated.
Table XV-8

SMALL CELL LUNG AND BRONCHUS CANCER (Invasive)

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

<table>
<thead>
<tr>
<th>Year of Diagnosis</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>1974-1976*</td>
<td>3.6</td>
<td>3.0</td>
<td>5.0</td>
<td>3.6</td>
<td>2.9</td>
<td>5.0</td>
<td>3.4</td>
<td>3.6</td>
<td>3.1</td>
</tr>
<tr>
<td>1977-1979*</td>
<td>4.5</td>
<td>3.3</td>
<td>6.7</td>
<td>4.5</td>
<td>3.3</td>
<td>6.7</td>
<td>3.8</td>
<td>3.4</td>
<td>4.8</td>
</tr>
<tr>
<td>1980-1982*</td>
<td>4.7</td>
<td>3.8</td>
<td>6.2</td>
<td>4.8</td>
<td>4.0</td>
<td>6.1</td>
<td>3.9</td>
<td>3.0</td>
<td>6.4</td>
</tr>
<tr>
<td>1983-1985*</td>
<td>4.7</td>
<td>3.5</td>
<td>6.6</td>
<td>4.8</td>
<td>3.6</td>
<td>6.6</td>
<td>4.7</td>
<td>2.5</td>
<td>8.6</td>
</tr>
<tr>
<td>1986-1988*</td>
<td>5.0</td>
<td>3.9</td>
<td>6.5</td>
<td>5.2</td>
<td>4.0</td>
<td>6.8</td>
<td>3.9</td>
<td>3.4</td>
<td>4.6</td>
</tr>
<tr>
<td>1989-1991*</td>
<td>5.4</td>
<td>4.5</td>
<td>6.5</td>
<td>5.5</td>
<td>4.3</td>
<td>6.9</td>
<td>3.7</td>
<td>4.3</td>
<td>2.9</td>
</tr>
<tr>
<td>1992-1994b</td>
<td>6.3</td>
<td>4.9</td>
<td>7.8</td>
<td>6.3</td>
<td>4.9</td>
<td>7.7</td>
<td>5.5</td>
<td>3.8</td>
<td>7.6</td>
</tr>
<tr>
<td>1995-2000b</td>
<td>6.5</td>
<td>5.6</td>
<td>7.4</td>
<td>6.6</td>
<td>5.6</td>
<td>7.6</td>
<td>5.4</td>
<td>5.0</td>
<td>5.9</td>
</tr>
</tbody>
</table>

STAGE DISTRIBUTION (%) 1995-2000*

<table>
<thead>
<tr>
<th>Stage</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>Localized</td>
<td>21.4</td>
<td>19.6</td>
<td>23.1</td>
<td>21.8</td>
<td>20.1</td>
<td>23.1</td>
<td>15.5</td>
<td>20.2</td>
<td>-</td>
</tr>
<tr>
<td>Regional</td>
<td>10.8</td>
<td>9.3</td>
<td>12.2</td>
<td>11.0</td>
<td>9.4</td>
<td>12.5</td>
<td>9.9</td>
<td>9.7</td>
<td>10.4</td>
</tr>
<tr>
<td>Distant</td>
<td>2.1</td>
<td>2.0</td>
<td>2.3</td>
<td>2.2</td>
<td>2.0</td>
<td>2.4</td>
<td>0.4</td>
<td>0.0</td>
<td>0.8</td>
</tr>
<tr>
<td>Unstaged</td>
<td>6.7</td>
<td>6.0</td>
<td>6.9</td>
<td>6.4</td>
<td>6.1</td>
<td>6.3</td>
<td>13.3</td>
<td>5.9</td>
<td>-</td>
</tr>
</tbody>
</table>

5-YR RELATIVE SURVIVAL RATES, 1995-2000*

<table>
<thead>
<tr>
<th>Age at Diagnosis</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
<th>Total</th>
<th>Males</th>
<th>Females</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;45</td>
<td>11.6</td>
<td>9.2</td>
<td>14.7</td>
<td>12.5</td>
<td>9.2</td>
<td>16.3</td>
<td>0.0</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>45-54</td>
<td>9.8</td>
<td>7.0</td>
<td>13.5</td>
<td>9.7</td>
<td>7.2</td>
<td>13.1</td>
<td>9.0</td>
<td>3.8</td>
<td>14.9</td>
</tr>
<tr>
<td>55-64</td>
<td>8.4</td>
<td>7.1</td>
<td>9.9</td>
<td>8.8</td>
<td>7.5</td>
<td>10.3</td>
<td>4.0</td>
<td>4.3</td>
<td>3.8</td>
</tr>
<tr>
<td>65-74</td>
<td>5.4</td>
<td>4.8</td>
<td>5.9</td>
<td>5.3</td>
<td>4.4</td>
<td>6.1</td>
<td>5.7</td>
<td>6.3</td>
<td>5.4</td>
</tr>
<tr>
<td>75+</td>
<td>3.4</td>
<td>3.3</td>
<td>3.6</td>
<td>3.5</td>
<td>3.3</td>
<td>3.7</td>
<td>3.3</td>
<td>4.4</td>
<td>0.0</td>
</tr>
<tr>
<td>Under 65</td>
<td>8.9</td>
<td>7.2</td>
<td>11.1</td>
<td>9.2</td>
<td>7.5</td>
<td>11.3</td>
<td>5.7</td>
<td>4.4</td>
<td>7.5</td>
</tr>
<tr>
<td>65 and over</td>
<td>4.7</td>
<td>4.3</td>
<td>5.1</td>
<td>4.7</td>
<td>4.0</td>
<td>5.3</td>
<td>5.1</td>
<td>5.7</td>
<td>4.5</td>
</tr>
</tbody>
</table>

* Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

b The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).
c The standard error of the survival rate is between 5 and 10 percentage points.
d The standard error of the survival rate is greater than 10 percentage points.
e Statistic could not be calculated.
## 5-YR Relative Survival Rates, 1995-2000

### Year of Diagnosis:

<table>
<thead>
<tr>
<th>Year</th>
<th>All Stages</th>
<th>Localized</th>
<th>Regional</th>
<th>Distant</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>1994</td>
<td>16.9%</td>
<td>51.3%</td>
<td>17.0%</td>
<td>2.2%</td>
<td>8.4%</td>
</tr>
<tr>
<td>1995</td>
<td>15.0%</td>
<td>47.1%</td>
<td>15.9%</td>
<td>2.1%</td>
<td>8.7%</td>
</tr>
<tr>
<td>1996</td>
<td>19.2%</td>
<td>16.3%</td>
<td>18.6%</td>
<td>2.3%</td>
<td>8.1%</td>
</tr>
<tr>
<td>1997</td>
<td>14.9%</td>
<td>15.8%</td>
<td>18.6%</td>
<td>2.3%</td>
<td>8.1%</td>
</tr>
<tr>
<td>1998</td>
<td>19.2%</td>
<td>15.8%</td>
<td>18.6%</td>
<td>2.3%</td>
<td>8.1%</td>
</tr>
</tbody>
</table>

### Stage Distribution (%) 1995-2000

<table>
<thead>
<tr>
<th>Stage</th>
<th>Number of Cases</th>
<th>Percent</th>
<th>Localized</th>
<th>Regional</th>
<th>Distant</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Stages</td>
<td>64,035</td>
<td>100%</td>
<td>18%</td>
<td>37%</td>
<td>36%</td>
<td>9%</td>
</tr>
<tr>
<td>Total</td>
<td>36,600</td>
<td>100%</td>
<td>16%</td>
<td>38%</td>
<td>37%</td>
<td>8%</td>
</tr>
<tr>
<td>Regional</td>
<td>27,435</td>
<td>100%</td>
<td>20%</td>
<td>36%</td>
<td>35%</td>
<td>9%</td>
</tr>
<tr>
<td>Localized</td>
<td>52,766</td>
<td>100%</td>
<td>18%</td>
<td>37%</td>
<td>36%</td>
<td>9%</td>
</tr>
<tr>
<td>Distant</td>
<td>29,469</td>
<td>100%</td>
<td>21%</td>
<td>38%</td>
<td>37%</td>
<td>9%</td>
</tr>
<tr>
<td>Unstaged</td>
<td>23,297</td>
<td>100%</td>
<td>21%</td>
<td>38%</td>
<td>37%</td>
<td>9%</td>
</tr>
</tbody>
</table>

### 5-YR Relative Survival Rates, 1995-2000

<table>
<thead>
<tr>
<th>Age at Diagnosis</th>
<th>All Races</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;45</td>
<td>23.4%</td>
<td>26.3%</td>
<td>16.7%</td>
</tr>
<tr>
<td>45-54</td>
<td>20.7%</td>
<td>21.4%</td>
<td>16.9%</td>
</tr>
<tr>
<td>55-64</td>
<td>19.2%</td>
<td>19.8%</td>
<td>14.7%</td>
</tr>
<tr>
<td>65-74</td>
<td>17.3%</td>
<td>17.6%</td>
<td>13.4%</td>
</tr>
<tr>
<td>75+</td>
<td>11.0%</td>
<td>11.0%</td>
<td>10.9%</td>
</tr>
<tr>
<td>Under 65</td>
<td>20.0%</td>
<td>20.8%</td>
<td>15.7%</td>
</tr>
<tr>
<td>65 and over</td>
<td>14.8%</td>
<td>15.0%</td>
<td>12.5%</td>
</tr>
</tbody>
</table>

---

* Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

* The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).

* The standard error of the survival rate is between 5 and 10 percentage points.

* The standard error of the survival rate is greater than 10 percentage points.

* Statistic could not be calculated.
### Table XVI-4
MELANOMA OF THE SKIN (Invasive)

<table>
<thead>
<tr>
<th>SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE</th>
</tr>
</thead>
<tbody>
<tr>
<td>All Races</td>
</tr>
<tr>
<td>Total</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td><strong>5-YR RELATIVE SURVIVAL RATES</strong></td>
</tr>
<tr>
<td>YEAR OF DIAGNOSIS:</td>
</tr>
<tr>
<td>1960-1963&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>1970-1973&lt;sup&gt;a&lt;/sup&gt;</td>
</tr>
<tr>
<td>1974-1976&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>1977-1979&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>1980-1982&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>1983-1985&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>1986-1988&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>1989-1991&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>1992-1994&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td>1995-2000&lt;sup&gt;b&lt;/sup&gt;</td>
</tr>
<tr>
<td><strong>STAGE DISTRIBUTION (%) 1995-2000&lt;sup&gt;b&lt;/sup&gt;</strong></td>
</tr>
<tr>
<td>ALL STAGES</td>
</tr>
<tr>
<td>Number of cases</td>
</tr>
<tr>
<td>Percent</td>
</tr>
<tr>
<td>LOCALIZED</td>
</tr>
<tr>
<td>REGIONAL</td>
</tr>
<tr>
<td>DISTANT</td>
</tr>
<tr>
<td>UNSTAGED</td>
</tr>
<tr>
<td><strong>5-YR RELATIVE SURVIVAL RATES, 1995-2000&lt;sup&gt;b&lt;/sup&gt;</strong></td>
</tr>
<tr>
<td>AGE AT DIAGNOSIS:</td>
</tr>
<tr>
<td>&lt;45</td>
</tr>
<tr>
<td>45-54</td>
</tr>
<tr>
<td>55-64</td>
</tr>
<tr>
<td>65-74</td>
</tr>
<tr>
<td>75+</td>
</tr>
<tr>
<td>Under 65</td>
</tr>
<tr>
<td>65 and over</td>
</tr>
</tbody>
</table>

---

* Rates are based on End Results data from a series of hospital registries and one population-based registry.

* Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

<sup>a</sup> The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).

<sup>b</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>c</sup> The standard error of the survival rate is greater than 10 percentage points.

<sup>d</sup> Statistic could not be calculated.
### Table XVII-4

#### MYELOMA

**SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR AND AGE**

| Year of Diagnosis | All Races | | | | Whites | | | | Blacks | | |
|-------------------|-----------|---|---|---|---|---|---|---|---|---|---|---|
|                   | Total     | Males | Females | | Total | Males | Females | | Total | Males | Females | |
| 1960-1963<sup>a</sup> | - | - | - | 12 | 13 | 10 | | | | | | |
| 1970-1973<sup>a</sup> | - | - | - | 19 | 20 | 17 | | | | | | |
| 1974-1976<sup>b</sup> | 24.5 | 23.9 | 25.1 | 24.1 | 23.3 | 25.0 | 27.7 | 28.2 | 27.3 | | |
| 1977-1979<sup>b</sup> | 26.4 | 25.9 | 26.8 | 24.8 | 25.2 | 24.3 | 34.4 | 30.0 | 38.8 | | |
| 1980-1982<sup>b</sup> | 28.1 | 25.9 | 30.3 | 27.9 | 26.3 | 29.4 | 29.7 | 27.3 | 32.2 | | |
| 1983-1985<sup>b</sup> | 28.1 | 28.2 | 28.0 | 27.4 | 27.2 | 27.5 | 31.2 | 33.9 | 28.2 | | |
| 1986-1988<sup>b</sup> | 29.4 | 30.7 | 28.2 | 29.3 | 31.0 | 27.5 | 31.6 | 29.6 | 33.2 | | |
| 1989-1991<sup>b</sup> | 30.0 | 31.2 | 28.7 | 29.2 | 30.0 | 28.3 | 34.0 | 38.2 | 30.1 | | |
| 1992-1994<sup>b</sup> | 30.4 | 30.8 | 30.0 | 29.5 | 30.2 | 28.7 | 34.0 | 34.2 | 33.8 | | |
| 1995-2000<sup>b</sup> | 32.1<sup>c</sup> | 35.6<sup>c</sup> | 28.4<sup>c</sup> | 31.9<sup>c</sup> | 35.2<sup>c</sup> | 28.3<sup>c</sup> | 32.1 | 35.2<sup>c</sup> | 29.6 | | |

#### 5-YR RELATIVE SURVIVAL RATES, 1995-2000<sup>b</sup>

| Age at Diagnosis | All Races | | | | Whites | | | | Blacks | | |
|------------------|-----------|---|---|---|---|---|---|---|---|---|---|---|
| Under 65<sup>a</sup> | 46.0 | 46.6<sup>d</sup> | 44.9<sup>d</sup> | 50.9 | 52.0<sup>d</sup> | 48.1<sup>d</sup> | 29.7<sup>d</sup> | 25.8<sup>d</sup> | 33.8<sup>c</sup> | | |
| 45-54<sup>b</sup> | 48.1 | 50.8 | 44.6 | 49.0 | 51.1 | 46.4 | 40.1<sup>d</sup> | 43.9<sup>d</sup> | 36.5<sup>d</sup> | | |
| 55-64<sup>b</sup> | 36.6 | 38.4 | 34.2 | 38.1 | 40.8 | 34.3 | 32.8 | 30.0<sup>d</sup> | 35.4<sup>d</sup> | | |
| 65-74<sup>b</sup> | 31.5 | 34.9 | 27.7 | 31.1 | 32.7 | 29.1 | 35.4 | 48.5<sup>d</sup> | 25.9 | | |
| 75+<sup>b</sup> | 19.3 | 20.6 | 18.5 | 19.2 | 20.5 | 18.2 | 21.0 | 18.3<sup>d</sup> | 22.4<sup>d</sup> | | |
| Under 65<sup>d</sup> | 41.7 | 43.7 | 39.0 | 43.4 | 45.6 | 40.0 | 34.9 | 34.1 | 35.6 | | |
| 65 and over<sup>d</sup> | 25.6 | 29.0 | 22.7 | 25.2 | 27.7 | 23.0 | 29.2 | 36.6<sup>d</sup> | 24.3 | | |

---

<sup>a</sup> Rates are based on End Results data from a series of hospital registries and one population-based registry.

<sup>b</sup> Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

<sup>c</sup> The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).

<sup>d</sup> The standard error of the survival rate is between 5 and 10 percentage points.

<sup>e</sup> The standard error of the survival rate is greater than 10 percentage points.

<sup>f</sup> Statistic could not be calculated.
Table XVIII-4
NON-HODGKIN LYMPHOMA

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR AND AGE

<table>
<thead>
<tr>
<th></th>
<th>All Races</th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td>Total</td>
<td>Males</td>
</tr>
<tr>
<td>5-YR RELATIVE SURVIVAL RATES</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YEAR OF DIAGNOSIS:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1960-1963*</td>
<td>31</td>
<td>31</td>
<td>31</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1970-1973*</td>
<td>40</td>
<td>39</td>
<td>40</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1974-1976*</td>
<td>54.0</td>
<td>52.8</td>
<td>55.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1980-1982*</td>
<td>51.4</td>
<td>50.2</td>
<td>52.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1983-1985*</td>
<td>50.5</td>
<td>52.7</td>
<td>48.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1986-1988*</td>
<td>52.2</td>
<td>52.5</td>
<td>51.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1989-1991*</td>
<td>52.8</td>
<td>52.4</td>
<td>52.2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1992-1994*</td>
<td>52.1</td>
<td>52.8</td>
<td>52.8</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1995-2000*</td>
<td>60.3</td>
<td>58.4</td>
<td>62.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-YR RELATIVE SURVIVAL RATES, 1995-2000*</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGE AT DIAGNOSIS:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;45</td>
<td>63.3</td>
<td>58.8</td>
<td>72.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>45-54</td>
<td>68.7</td>
<td>63.5</td>
<td>76.9</td>
<td></td>
<td></td>
</tr>
<tr>
<td>55-64</td>
<td>64.6</td>
<td>60.9</td>
<td>69.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>65-74</td>
<td>57.8</td>
<td>55.6</td>
<td>60.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>75+</td>
<td>43.9</td>
<td>44.4</td>
<td>43.7</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Under 65</td>
<td>65.3</td>
<td>60.8</td>
<td>72.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>65 and over</td>
<td>51.5</td>
<td>51.1</td>
<td>52.0</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Rates are based on End Results data from a series of hospital registries and one population-based registry.

The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).

The standard error of the survival rate is greater than 10 percentage points.

Statistic could not be calculated.
### Table XIX-4

**ORAL CAVITY AND PHARYNX CANCER (Invasive)**

**SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE**

<table>
<thead>
<tr>
<th>All Races</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total Males</td>
<td>Total Males</td>
</tr>
<tr>
<td></td>
<td>Females</td>
<td>Females</td>
</tr>
<tr>
<td><strong>5-YR RELATIVE SURVIVAL RATES</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YEAR OF DIAGNOSIS:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1960-1963*</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1970-1973*</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1974-1976*</td>
<td>53.5</td>
<td>52.5</td>
</tr>
<tr>
<td>1977-1979*</td>
<td>52.9</td>
<td>51.7</td>
</tr>
<tr>
<td>1980-1982*</td>
<td>53.0</td>
<td>51.4</td>
</tr>
<tr>
<td>1983-1985*</td>
<td>53.4</td>
<td>51.8</td>
</tr>
<tr>
<td>1986-1988*</td>
<td>53.1</td>
<td>49.6</td>
</tr>
<tr>
<td>1989-1991*</td>
<td>53.3</td>
<td>49.5</td>
</tr>
<tr>
<td>1992-1994*</td>
<td>55.9</td>
<td>53.5</td>
</tr>
<tr>
<td>1995-2000*</td>
<td>58.7*</td>
<td>57.4*</td>
</tr>
<tr>
<td>1995-2000b</td>
<td>58.7</td>
<td>57.4</td>
</tr>
<tr>
<td><strong>STAGE DISTRIBUTION (%) 1995-2000</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of cases</td>
<td>13,249</td>
<td>9,037</td>
</tr>
<tr>
<td>Percent</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>LOCALIZED</td>
<td>34</td>
<td>32</td>
</tr>
<tr>
<td>REGIONAL</td>
<td>50</td>
<td>52</td>
</tr>
<tr>
<td>DISTANT</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>UNSTAGED</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td><strong>5-YR RELATIVE SURVIVAL RATES, 1995-2000</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGE AT DIAGNOSIS:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;45</td>
<td>74.2</td>
<td>69.2</td>
</tr>
<tr>
<td>45-54</td>
<td>62.6</td>
<td>60.6</td>
</tr>
<tr>
<td>55-64</td>
<td>57.2</td>
<td>55.6</td>
</tr>
<tr>
<td>65-74</td>
<td>54.6</td>
<td>54.3</td>
</tr>
<tr>
<td>75+</td>
<td>47.0</td>
<td>48.3</td>
</tr>
<tr>
<td>Under 65</td>
<td>63.1</td>
<td>60.3</td>
</tr>
<tr>
<td>65 and over</td>
<td>51.9</td>
<td>52.5</td>
</tr>
</tbody>
</table>

* Rates are based on End Results data from a series of hospital registries and one population-based registry.

b Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

c The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).

d The standard error of the survival rate is between 5 and 10 percentage points.

e The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated.
Table XX-4
OVARY CANCER (Invasive)

SURVIVAL RATES, BY RACE, DIAGNOSIS YEAR, STAGE AND AGE

<table>
<thead>
<tr>
<th>All Races, Females</th>
<th>White Females</th>
<th>Black Females</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;65</td>
<td>65+</td>
</tr>
</tbody>
</table>

5-YR RELATIVE SURVIVAL RATES

YEAR OF DIAGNOSIS:

1960-1963a  32  –  –  32  –  –  32  –  –
1974-1976b  37.0  43.1  23.8  36.6  42.8  23.5  41.2  44.9  33.2d
1977-1979b  38.5  46.7  22.4  37.9  46.0  22.8  39.8  49.1  10.1
1980-1982b  39.1  48.3  23.5  38.7  48.2  23.4  39.3  47.1  22.8d
1983-1985b  41.0  50.7  25.9  40.3  50.0  25.8  41.5  52.3  20.7
1986-1988b  39.7  51.1  23.8  39.4  51.0  24.0  36.6  47.4  19.8
1989-1991b  40.9  53.4  25.2  41.2  54.1  25.5  30.7  42.8  16.5
1992-1994b  43.0  55.3  27.4  42.1  55.0  26.8  46.2  56.5  28.4
1995-2000b  44.0e  55.7  28.8  44.0e  56.1  28.9  37.9  49.7e  20.8e

STAGE DISTRIBUTION (%) 1995-2000b

<table>
<thead>
<tr>
<th>All Stages</th>
<th>Number of cases</th>
<th>Percent</th>
<th>LOCALIZED</th>
<th>REGIONAL</th>
<th>DISTANT</th>
<th>UNSTAGED</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>9645</td>
<td>5043</td>
<td>5402</td>
<td>8316</td>
<td>4216</td>
<td>4100</td>
</tr>
<tr>
<td>ALL STAGES</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>LOCALIZED</td>
<td>19%</td>
<td>27%</td>
<td>10%</td>
<td>18%</td>
<td>27%</td>
<td>10%</td>
</tr>
<tr>
<td>REGIONAL</td>
<td>7%</td>
<td>8%</td>
<td>5%</td>
<td>7%</td>
<td>8%</td>
<td>5%</td>
</tr>
<tr>
<td>DISTANT</td>
<td>68%</td>
<td>61%</td>
<td>75%</td>
<td>68%</td>
<td>62%</td>
<td>76%</td>
</tr>
<tr>
<td>UNSTAGED</td>
<td>7%</td>
<td>4%</td>
<td>10%</td>
<td>7%</td>
<td>4%</td>
<td>10%</td>
</tr>
</tbody>
</table>

5-YR RELATIVE SURVIVAL RATES, 1995-2000b

AGE AT DIAGNOSIS:

<45  72.3  –  –  73.1  –  –  71.4d  –  –
45-54 52.9  –  –  54.1  –  –  37.5d  –  –
55-64 46.4  –  –  46.8  –  –  39.9d  –  –
65-74 35.7  –  –  35.7  –  –  24.0  –  –
75+  20.3  –  –  20.8  –  –  15.1d  –  –
Under 65 55.7  –  –  56.1  –  –  49.7  –  –
65 and over 28.8  –  –  28.9  –  –  20.8  –  –

a Rates are based on End Results data from a series of hospital registries and one population-based registry.
b Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.
c The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).
d The standard error of the survival rate is between 5 and 10 percentage points.
e The standard error of the survival rate is greater than 10 percentage points.

Notes:
- All Races, Females
- White Females
- Black Females

References:
- Rates are based on End Results data from a series of hospital registries and one population-based registry.
- Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.
- The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).
- The standard error of the survival rate is between 5 and 10 percentage points.
- The standard error of the survival rate is greater than 10 percentage points.
Table XXI-4

PANCERAS CANCER (Invasive)

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

All Races  Whites  Blacks

<table>
<thead>
<tr>
<th>Year of Diagnosis</th>
<th>All Stages</th>
<th>Localized</th>
<th>Distal</th>
<th>Unstaged</th>
<th>All Stages</th>
<th>Localized</th>
<th>Distal</th>
<th>Unstaged</th>
<th>All Stages</th>
<th>Localized</th>
<th>Distal</th>
<th>Unstaged</th>
</tr>
</thead>
<tbody>
<tr>
<td>1960-1963a</td>
<td>1-2</td>
<td>1-2</td>
<td>1-2</td>
<td></td>
<td>1-2</td>
<td>1-2</td>
<td></td>
<td></td>
<td>1-2</td>
<td>1-2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1970-1973a</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td></td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
<td>2</td>
<td>2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1974-1976a</td>
<td>2.6</td>
<td>2.6</td>
<td>2.6</td>
<td></td>
<td>2.6</td>
<td>2.6</td>
<td></td>
<td></td>
<td>2.6</td>
<td>2.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1977-1979a</td>
<td>2.4</td>
<td>2.4</td>
<td>2.4</td>
<td></td>
<td>2.4</td>
<td>2.4</td>
<td></td>
<td></td>
<td>2.4</td>
<td>2.4</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1980-1982b</td>
<td>3.0</td>
<td>3.0</td>
<td>3.0</td>
<td></td>
<td>3.0</td>
<td>3.0</td>
<td></td>
<td></td>
<td>3.0</td>
<td>3.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1983-1985b</td>
<td>3.3</td>
<td>3.3</td>
<td>3.3</td>
<td></td>
<td>3.3</td>
<td>3.3</td>
<td></td>
<td></td>
<td>3.3</td>
<td>3.3</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1986-1988b</td>
<td>3.6</td>
<td>3.6</td>
<td>3.6</td>
<td></td>
<td>3.6</td>
<td>3.6</td>
<td></td>
<td></td>
<td>3.6</td>
<td>3.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1989-1991b</td>
<td>4.0</td>
<td>4.0</td>
<td>4.0</td>
<td></td>
<td>4.0</td>
<td>4.0</td>
<td></td>
<td></td>
<td>4.0</td>
<td>4.0</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1992-1994b</td>
<td>4.6</td>
<td>4.6</td>
<td>4.6</td>
<td></td>
<td>4.6</td>
<td>4.6</td>
<td></td>
<td></td>
<td>4.6</td>
<td>4.6</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1995-2000b</td>
<td>4.4c</td>
<td>4.4c</td>
<td>4.4c</td>
<td></td>
<td>4.4c</td>
<td>4.4c</td>
<td></td>
<td></td>
<td>4.4c</td>
<td>4.4c</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

5-YR RELATIVE SURVIVAL RATES, 1995-2000b

<table>
<thead>
<tr>
<th>Age at Diagnosis</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;45</td>
<td>15.5</td>
<td>13.0</td>
</tr>
<tr>
<td>45-54</td>
<td>15.6</td>
<td>13.0</td>
</tr>
<tr>
<td>55-64</td>
<td>4.1</td>
<td>4.0</td>
</tr>
<tr>
<td>65-74</td>
<td>3.5</td>
<td>3.1</td>
</tr>
<tr>
<td>75+</td>
<td>2.8</td>
<td>2.7</td>
</tr>
<tr>
<td>Under 65</td>
<td>6.4</td>
<td>5.5</td>
</tr>
<tr>
<td>65 and over</td>
<td>3.1</td>
<td>3.0</td>
</tr>
</tbody>
</table>

a Rates are based on End Results data from a series of hospital registries and one population-based registry.

b Rates are from the SEER 9 areas. They are based on population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

c The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).
d The standard error of the survival rate is between 5 and 10 percentage points.
e The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated.
### Table XXII-4

**SURVIVAL RATES, BY RACE, DIAGNOSIS YEAR, STAGE AND AGE**

<table>
<thead>
<tr>
<th></th>
<th>All Races, Males</th>
<th>White Males</th>
<th>Black Males</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>&lt;65 65+</td>
<td>&lt;65 65+</td>
<td>&lt;65 65+</td>
</tr>
<tr>
<td><strong>5-YR RELATIVE SURVIVAL RATES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>YEAR OF DIAGNOSIS:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1960-1963*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1970-1973*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1974-1976*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1977-1979*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1980-1982*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1983-1985*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1986-1988*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1989-1991*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1992-1994*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1995-2000*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>STAGE DISTRIBUTION (%) 1995-2000</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ALL STAGES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of cases</td>
<td>96,225</td>
<td>31,566</td>
<td>64,659</td>
</tr>
<tr>
<td>Percent</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td><strong>LOCAL/REGIONAL</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of cases</td>
<td>90</td>
<td>94</td>
<td>88</td>
</tr>
<tr>
<td>Percent</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td><strong>DISTANT</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of cases</td>
<td>5</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>Percent</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td><strong>UNSTAGED</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Number of cases</td>
<td>5</td>
<td>3</td>
<td>6</td>
</tr>
<tr>
<td>Percent</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td><strong>5-YR RELATIVE SURVIVAL RATES, 1995-2000</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>AGE AT DIAGNOSIS:</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;45</td>
<td>91.7</td>
<td>91.3</td>
<td>95.4</td>
</tr>
<tr>
<td>45-54</td>
<td>97.2</td>
<td>97.5</td>
<td>96.8</td>
</tr>
<tr>
<td>55-64</td>
<td>99.7</td>
<td>100.0</td>
<td>98.4</td>
</tr>
<tr>
<td>65-74</td>
<td>100.0</td>
<td>100.0</td>
<td>98.1</td>
</tr>
<tr>
<td>75+</td>
<td>94.8</td>
<td>96.0</td>
<td>87.5</td>
</tr>
<tr>
<td>Under 65</td>
<td>99.1</td>
<td>99.5</td>
<td>98.1</td>
</tr>
<tr>
<td>65 and over</td>
<td>99.7</td>
<td>100.0</td>
<td>95.1</td>
</tr>
</tbody>
</table>

* Rates are based on End Results data from a series of hospital registries and one population-based registry.

b Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

c The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).

d The standard error of the survival rate is between 5 and 10 percentage points.

e The standard error of the survival rate is greater than 10 percentage points.

- Statistic could not be calculated.
### Table XXIII-4

**STOMACH CANCER (Invasive)**

**SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE**

<table>
<thead>
<tr>
<th></th>
<th>All Races</th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>YEAR OF DIAGNOSIS:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1960–1963a</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>11</td>
<td>10</td>
<td>13</td>
</tr>
<tr>
<td>1970–1973a</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>13</td>
<td>12</td>
<td>14</td>
</tr>
<tr>
<td>1974–1976b</td>
<td>15.3</td>
<td>14.1</td>
<td>17.3</td>
<td>14.6</td>
<td>13.4</td>
<td>16.6</td>
</tr>
<tr>
<td>1977–1979b</td>
<td>16.4</td>
<td>15.0</td>
<td>18.6</td>
<td>15.7</td>
<td>14.1</td>
<td>18.2</td>
</tr>
<tr>
<td>1980–1982b</td>
<td>17.7</td>
<td>16.6</td>
<td>19.6</td>
<td>16.5</td>
<td>15.6</td>
<td>18.0</td>
</tr>
<tr>
<td>1983–1985b</td>
<td>17.4</td>
<td>15.9</td>
<td>19.8</td>
<td>16.3</td>
<td>14.6</td>
<td>19.0</td>
</tr>
<tr>
<td>1989–1991b</td>
<td>21.1</td>
<td>17.6</td>
<td>26.8</td>
<td>18.4</td>
<td>15.1</td>
<td>24.0</td>
</tr>
<tr>
<td>1992–1994b</td>
<td>21.8</td>
<td>20.5</td>
<td>24.0</td>
<td>21.0</td>
<td>19.7</td>
<td>23.3</td>
</tr>
<tr>
<td>1995–2000b</td>
<td>23.3</td>
<td>22.1</td>
<td>25.4</td>
<td>21.5</td>
<td>19.9</td>
<td>24.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>24.2</td>
<td>21.4</td>
<td>27.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>63.1</td>
<td>57.0</td>
<td>66.0</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>22.6</td>
<td>23.0</td>
<td>21.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.6</td>
<td>2.2</td>
<td>3.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>19.1</td>
<td>15.6</td>
<td>20.1</td>
</tr>
<tr>
<td>1995–2000b</td>
<td>ALL STAGES</td>
<td>23.3</td>
<td>22.1</td>
<td>25.4</td>
<td>242.2</td>
<td>21.4</td>
</tr>
<tr>
<td></td>
<td>LOCALIZED</td>
<td>58.4</td>
<td>56.4</td>
<td>61.4</td>
<td>54.2</td>
<td>50.7</td>
</tr>
<tr>
<td></td>
<td>REGIONAL</td>
<td>22.5</td>
<td>21.5</td>
<td>24.0</td>
<td>20.9</td>
<td>20.1</td>
</tr>
<tr>
<td></td>
<td>DISTANT</td>
<td>3.1</td>
<td>3.0</td>
<td>3.0</td>
<td>2.7</td>
<td>2.6</td>
</tr>
<tr>
<td></td>
<td>UNSTAGED</td>
<td>12.5</td>
<td>13.0</td>
<td>11.7</td>
<td>11.1</td>
<td>11.8</td>
</tr>
<tr>
<td>STAGE DISTRIBUTION (%) 1995–2000b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALL STAGES</td>
<td>Number of cases</td>
<td>10,067</td>
<td>6,193</td>
<td>3,874</td>
<td>7,074</td>
<td>4,444</td>
</tr>
<tr>
<td></td>
<td>Percent</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td></td>
<td>LOCALIZED</td>
<td>24</td>
<td>23</td>
<td>26</td>
<td>24</td>
<td>23</td>
</tr>
<tr>
<td></td>
<td>REGIONAL</td>
<td>32</td>
<td>33</td>
<td>30</td>
<td>31</td>
<td>32</td>
</tr>
<tr>
<td></td>
<td>DISTANT</td>
<td>32</td>
<td>34</td>
<td>29</td>
<td>32</td>
<td>34</td>
</tr>
<tr>
<td></td>
<td>UNSTAGED</td>
<td>12</td>
<td>10</td>
<td>16</td>
<td>13</td>
<td>11</td>
</tr>
<tr>
<td>5-YR RELATIVE SURVIVAL RATES, 1995–2000b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>AGE AT DIAGNOSIS:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;45</td>
<td>28.0</td>
<td>25.6</td>
<td>31.7</td>
<td>29.8</td>
<td>25.6</td>
<td>36.6</td>
</tr>
<tr>
<td>45–54</td>
<td>25.4</td>
<td>22.1</td>
<td>32.9</td>
<td>23.3</td>
<td>20.0</td>
<td>32.0</td>
</tr>
<tr>
<td>55–64</td>
<td>23.6</td>
<td>22.5</td>
<td>26.2</td>
<td>21.3</td>
<td>19.8</td>
<td>24.7</td>
</tr>
<tr>
<td>65–74</td>
<td>25.5</td>
<td>24.2</td>
<td>28.0</td>
<td>22.6</td>
<td>21.9</td>
<td>24.3</td>
</tr>
<tr>
<td>75+</td>
<td>19.4</td>
<td>18.3</td>
<td>20.6</td>
<td>18.2</td>
<td>16.4</td>
<td>20.1</td>
</tr>
<tr>
<td>Under 65</td>
<td>25.0</td>
<td>22.9</td>
<td>29.4</td>
<td>23.4</td>
<td>20.9</td>
<td>29.4</td>
</tr>
<tr>
<td>65 and over</td>
<td>22.3</td>
<td>21.5</td>
<td>23.5</td>
<td>20.3</td>
<td>19.4</td>
<td>21.7</td>
</tr>
</tbody>
</table>

* Rates are based on End Results data from a series of hospital registries and one population-based registry.

b Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

c The difference in rates between 1974–1976 and 1995–2000 is statistically significant (p<.05).

d The standard error of the survival rate is greater than 10 percentage points.

e Statistic could not be calculated.
### Table XXIV-4
#### TESTIS CANCER (Invasive)

**SURVIVAL RATES, BY RACE, DIAGNOSIS YEAR, STAGE AND AGE**

<table>
<thead>
<tr>
<th>Age</th>
<th>All Races, Males</th>
<th>White Males</th>
<th>Black Males</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>All &lt;50 50+</td>
<td>All &lt;50 50+</td>
<td>All &lt;50 50+</td>
</tr>
<tr>
<td>1960-1963a</td>
<td>- - - 63 - -</td>
<td>- - - 63 - -</td>
<td>- - - 63 - -</td>
</tr>
<tr>
<td>1970-1973a</td>
<td>- - - 72 - -</td>
<td>- - - 72 - -</td>
<td>- - - 72 - -</td>
</tr>
<tr>
<td>1974-1976a</td>
<td>78.7 78.1 82.9</td>
<td>78.8 78.2 83.3</td>
<td>75.9d - -</td>
</tr>
<tr>
<td>1977-1979a</td>
<td>87.5 88.6 77.1</td>
<td>87.9 89.0 78.1</td>
<td>66.2a - -</td>
</tr>
<tr>
<td>1980-1982a</td>
<td>91.9 91.9 91.8</td>
<td>92.1 92.0 92.7</td>
<td>89.7d 89.2d -</td>
</tr>
<tr>
<td>1983-1985a</td>
<td>91.0 91.8 82.3</td>
<td>91.3 92.3 80.7</td>
<td>87.9d 84.3d -</td>
</tr>
<tr>
<td>1986-1988a</td>
<td>95.2 95.3 93.5</td>
<td>95.7 95.7 94.4</td>
<td>- - -</td>
</tr>
<tr>
<td>1989-1991a</td>
<td>95.4 95.5 93.8</td>
<td>95.9 95.8 94.8</td>
<td>89.8d 93.6d -</td>
</tr>
<tr>
<td>1992-1994a</td>
<td>95.4 95.7 90.4</td>
<td>95.6 95.9 90.1</td>
<td>85.2d 84.5d -</td>
</tr>
<tr>
<td>1995-2000b</td>
<td>95.9c 96.4d 88.3</td>
<td>96.2c 96.7c 89.4</td>
<td>87.3 90.4 -</td>
</tr>
<tr>
<td></td>
<td>95.9 96.4 88.3</td>
<td>96.2 96.7 89.4</td>
<td>87.3 90.4 -</td>
</tr>
<tr>
<td>LOCALIZED</td>
<td>99.4 99.4 97.0</td>
<td>99.4 99.4 97.6</td>
<td>96.5d 99.6 -</td>
</tr>
<tr>
<td>REGIONAL</td>
<td>95.9 96.4 89.9d</td>
<td>96.1 96.5 90.6d</td>
<td>- - -</td>
</tr>
<tr>
<td>DISTANT</td>
<td>71.8 75.1 38.7d</td>
<td>73.1 76.6 39.5d</td>
<td>- - -</td>
</tr>
<tr>
<td>UNSTAGED</td>
<td>89.1 91.6 -</td>
<td>90.2 93.0 -</td>
<td>- - -</td>
</tr>
</tbody>
</table>

#### STAGE DISTRIBUTION (%) 1995-2000b

<table>
<thead>
<tr>
<th>Stage Distribution (%)</th>
<th>1995-2000b</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALL STAGES</td>
<td>4,148 3,827 321 3,822 3,521 301 121 113 8</td>
</tr>
<tr>
<td>Percent</td>
<td>100% 100% 100% 100% 100% 100% 100% 100% 100%</td>
</tr>
<tr>
<td>LOCALIZED</td>
<td>70 71 67</td>
</tr>
<tr>
<td>REGIONAL</td>
<td>18 18 17</td>
</tr>
<tr>
<td>DISTANT</td>
<td>10 10 13</td>
</tr>
<tr>
<td>UNSTAGED</td>
<td>1 1 2</td>
</tr>
</tbody>
</table>

#### 5-YR RELATIVE SURVIVAL RATES, 1995-2000b

<table>
<thead>
<tr>
<th>Age at Diagnosis</th>
<th>&lt;45</th>
<th>45-54</th>
<th>55-64</th>
<th>65-74</th>
<th>75+</th>
<th>Under 65</th>
<th>65 and over</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survival Rate</td>
<td>96.5</td>
<td>94.5</td>
<td>87.2</td>
<td>74.2d</td>
<td>-</td>
<td>96.1</td>
<td>73.8d</td>
</tr>
<tr>
<td>Statistic</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

---

a Rates are based on End Results data from a series of hospital registries and one population-based registry.
b Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.
c The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).
d The standard error of the survival rate is between 5 and 10 percentage points.
e The standard error of the survival rate is greater than 10 percentage points.
f Statistic could not be calculated.
### SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

#### 5-YR RELATIVE SURVIVAL RATES

**YEAR OF DIAGNOSIS:**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td>61.3</td>
<td>72.0</td>
<td>76.3</td>
<td>78.3</td>
<td>81.3</td>
<td>84.2</td>
<td>86.1</td>
<td>88.3</td>
<td>90.3</td>
<td>91.4</td>
</tr>
<tr>
<td><strong>Males</strong></td>
<td>56.7</td>
<td>65.9</td>
<td>69.1</td>
<td>71.1</td>
<td>75.1</td>
<td>78.0</td>
<td>80.9</td>
<td>83.1</td>
<td>85.2</td>
<td>86.2</td>
</tr>
<tr>
<td><strong>Females</strong></td>
<td>65.9</td>
<td>72.3</td>
<td>76.4</td>
<td>78.6</td>
<td>82.1</td>
<td>85.0</td>
<td>87.1</td>
<td>89.6</td>
<td>91.5</td>
<td>92.3</td>
</tr>
</tbody>
</table>

#### STAGE DISTRIBUTION (%)

<table>
<thead>
<tr>
<th>ALL STAGES</th>
<th>9,436</th>
<th>2,276</th>
<th>7,160</th>
<th>7,850</th>
<th>1,971</th>
<th>5,879</th>
<th>528</th>
<th>89</th>
<th>439</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cases</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>Localized</td>
<td>57</td>
<td>46</td>
<td>61</td>
<td>57</td>
<td>46</td>
<td>61</td>
<td>60</td>
<td>54</td>
<td>62</td>
</tr>
<tr>
<td>Regional</td>
<td>35</td>
<td>43</td>
<td>33</td>
<td>35</td>
<td>43</td>
<td>32</td>
<td>30</td>
<td>27</td>
<td>31</td>
</tr>
<tr>
<td>Distant</td>
<td>5</td>
<td>9</td>
<td>4</td>
<td>5</td>
<td>9</td>
<td>4</td>
<td>7</td>
<td>16</td>
<td>5</td>
</tr>
<tr>
<td>Unstaged</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>2</td>
<td>3</td>
<td>3</td>
<td>3</td>
<td>3</td>
</tr>
</tbody>
</table>

#### 5-YR RELATIVE SURVIVAL RATES, 1995-2000<sup>b</sup>

**AGE AT DIAGNOSIS:**

| Under 10 | 99.4 | 98.2 | 99.6 | 99.6 | 99.0 | 99.7 | 97.8 | 87.5<sup>d</sup> | 99.2 |
| 10-19 | 98.4 | 96.1 | 99.1 | 98.9 | 97.4 | 99.5 | 92.2 | – | 94.7 |
| 20-24 | 93.5 | 88.8 | 95.6 | 93.2 | 88.1 | 95.7 | 98.3 | – | 97.6 |
| 25-34 | 90.4 | 87.2 | 91.9 | 90.4 | 86.6 | 92.0 | 90.9<sup>d</sup> | – | 90.7<sup>e</sup> |
| 35+ | 68.7 | 61.5<sup>d</sup> | 71.3 | 70.6 | 56.8<sup>d</sup> | 75.1<sup>d</sup> | 58.1<sup>d</sup> | – | 55.9<sup>d</sup> |

* Rates are based on End Results data from a series of hospital registries and one population-based registry.
* Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.
* The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).
* The standard error of the survival rate is greater than 10 percentage points.
* Statistic could not be calculated.
Table XXVI-4

SURVIVAL RATES, BY RACE, SEX, DIAGNOSIS YEAR, STAGE AND AGE

<table>
<thead>
<tr>
<th>YEAR OF DIAGNOSIS</th>
<th>All Races</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Males</td>
<td>Females</td>
</tr>
<tr>
<td>5-YR RELATIVE SURVIVAL RATES</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1960-1963a</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1970-1973a</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>1974-1976b</td>
<td>72.7</td>
<td>73.9</td>
<td>69.5</td>
</tr>
<tr>
<td>1977-1979b</td>
<td>75.1</td>
<td>76.8</td>
<td>70.6</td>
</tr>
<tr>
<td>1980-1982b</td>
<td>78.0</td>
<td>79.2</td>
<td>74.8</td>
</tr>
<tr>
<td>1983-1985b</td>
<td>77.7</td>
<td>79.3</td>
<td>73.2</td>
</tr>
<tr>
<td>1986-1988b</td>
<td>79.9</td>
<td>81.6</td>
<td>75.1</td>
</tr>
<tr>
<td>1989-1991b</td>
<td>81.0</td>
<td>83.5</td>
<td>73.9</td>
</tr>
<tr>
<td>1992-1994b</td>
<td>81.6</td>
<td>84.0</td>
<td>75.0</td>
</tr>
<tr>
<td>1995-2000b</td>
<td>81.7c</td>
<td>83.7c</td>
<td>76.2c</td>
</tr>
</tbody>
</table>

1995-2000b

STAGE DISTRIBUTION (%) 1995-2000b

<table>
<thead>
<tr>
<th>ALL STAGES</th>
<th>Number of cases</th>
<th>23,885</th>
<th>17,734</th>
<th>6,151</th>
<th>21,928</th>
<th>16,398</th>
<th>5,530</th>
<th>1,025</th>
<th>645</th>
<th>380</th>
</tr>
</thead>
<tbody>
<tr>
<td>Percent</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
<td>100%</td>
</tr>
<tr>
<td>LOCALIZED</td>
<td>74</td>
<td>76</td>
<td>71</td>
<td>75</td>
<td>76</td>
<td>72</td>
<td>58</td>
<td>62</td>
<td>51</td>
<td></td>
</tr>
<tr>
<td>REGIONAL</td>
<td>19</td>
<td>18</td>
<td>21</td>
<td>18</td>
<td>18</td>
<td>20</td>
<td>30</td>
<td>25</td>
<td>37</td>
<td></td>
</tr>
<tr>
<td>DISTANT</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>6</td>
<td>6</td>
<td>5</td>
<td></td>
</tr>
<tr>
<td>UNSTAGED</td>
<td>4</td>
<td>3</td>
<td>4</td>
<td>3</td>
<td>3</td>
<td>4</td>
<td>7</td>
<td>7</td>
<td>7</td>
<td></td>
</tr>
</tbody>
</table>

5-YR RELATIVE SURVIVAL RATES, 1995-2000b

AGE AT DIAGNOSIS:

<table>
<thead>
<tr>
<th></th>
<th>All Races</th>
<th>Whites</th>
<th>Blacks</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;45</td>
<td>90.4</td>
<td>91.4</td>
<td>87.1</td>
</tr>
<tr>
<td>45-54</td>
<td>86.6</td>
<td>87.7</td>
<td>83.4</td>
</tr>
<tr>
<td>55-64</td>
<td>84.6</td>
<td>85.9</td>
<td>80.3</td>
</tr>
<tr>
<td>65-74</td>
<td>82.3</td>
<td>84.0</td>
<td>77.2</td>
</tr>
<tr>
<td>75+</td>
<td>75.2</td>
<td>77.8</td>
<td>69.6</td>
</tr>
<tr>
<td>Under 65</td>
<td>85.9</td>
<td>87.1</td>
<td>82.2</td>
</tr>
<tr>
<td>65 and over</td>
<td>79.4</td>
<td>81.8</td>
<td>73.4</td>
</tr>
<tr>
<td>Age/Site</td>
<td>SEER Incidence</td>
<td>US Mortality</td>
<td>Survival</td>
</tr>
<tr>
<td>----------------------------------</td>
<td>----------------</td>
<td>--------------</td>
<td>----------</td>
</tr>
<tr>
<td></td>
<td>Num Cases Rate</td>
<td>Num Deaths Rate</td>
<td>APC</td>
</tr>
<tr>
<td>All Sites</td>
<td>1,888</td>
<td>2,456</td>
<td>56.7*</td>
</tr>
<tr>
<td></td>
<td>20.4 0.8c</td>
<td>2.6 -2.9c</td>
<td>74.2</td>
</tr>
<tr>
<td></td>
<td>1,228</td>
<td>129</td>
<td>59.9*</td>
</tr>
<tr>
<td>Soft tissue</td>
<td>127</td>
<td>129</td>
<td>74.2</td>
</tr>
<tr>
<td></td>
<td>1.4 0.4</td>
<td>0.1 -2.0c</td>
<td>89.7</td>
</tr>
<tr>
<td></td>
<td>0.4</td>
<td>-0.1</td>
<td>51.4</td>
</tr>
<tr>
<td>Kidney and Renal pelvis</td>
<td>190</td>
<td>109</td>
<td>32.8*</td>
</tr>
<tr>
<td></td>
<td>2.1 0.3</td>
<td>0.1 -3.9c</td>
<td>54.6</td>
</tr>
<tr>
<td>Eye and Orbit</td>
<td>126</td>
<td>31</td>
<td>38.9</td>
</tr>
<tr>
<td></td>
<td>1.4 0.9</td>
<td>0.0 -3.7c</td>
<td>46.7</td>
</tr>
<tr>
<td>Brain and Other nervous</td>
<td>359</td>
<td>623</td>
<td>51.2</td>
</tr>
<tr>
<td></td>
<td>3.9 1.5c</td>
<td>0.6 -1.2c</td>
<td>55.4</td>
</tr>
<tr>
<td>Other endocrine</td>
<td>129</td>
<td>406</td>
<td>54.6</td>
</tr>
<tr>
<td></td>
<td>1.4</td>
<td>-</td>
<td>54.6</td>
</tr>
<tr>
<td>Leukemia</td>
<td>671</td>
<td>802</td>
<td>38.9</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>545</td>
<td>267</td>
<td>58.4</td>
</tr>
<tr>
<td></td>
<td>5.9 0.8c</td>
<td>0.3 -5.0c</td>
<td>55.4</td>
</tr>
<tr>
<td>Ages 0-4</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites</td>
<td>1,104</td>
<td>2,525</td>
<td>55.1*</td>
</tr>
<tr>
<td></td>
<td>11.4 0.4</td>
<td>2.5 -3.2c</td>
<td>54.4</td>
</tr>
<tr>
<td>Brain and Other nervous</td>
<td>300</td>
<td>850</td>
<td>58.1</td>
</tr>
<tr>
<td></td>
<td>3.1 0.4</td>
<td>0.8 -1.0c</td>
<td>58.1</td>
</tr>
<tr>
<td>Leukemia</td>
<td>375</td>
<td>742</td>
<td>46.7</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>323</td>
<td>397</td>
<td>53.8</td>
</tr>
<tr>
<td></td>
<td>3.3 1.1c</td>
<td>0.4 -6.1c</td>
<td>53.8</td>
</tr>
<tr>
<td>Ages 5-9</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites</td>
<td>1,228</td>
<td>2,552</td>
<td>55.1*</td>
</tr>
<tr>
<td></td>
<td>12.9 0.9c</td>
<td>2.5 -2.4c</td>
<td>54.4</td>
</tr>
<tr>
<td>Bone and Joint</td>
<td>125</td>
<td>285</td>
<td>58.1</td>
</tr>
<tr>
<td></td>
<td>1.3 0.3</td>
<td>0.3 -1.7c</td>
<td>58.1</td>
</tr>
<tr>
<td>Brain and Other nervous</td>
<td>270</td>
<td>674</td>
<td>75.0</td>
</tr>
<tr>
<td></td>
<td>2.8 1.6c</td>
<td>0.7 -1.4c</td>
<td>75.0</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>118</td>
<td>35</td>
<td>28.8</td>
</tr>
<tr>
<td></td>
<td>1.2 -0.7c</td>
<td>-1.1 -0.7c</td>
<td>28.8</td>
</tr>
<tr>
<td>Leukemia</td>
<td>240</td>
<td>895</td>
<td>37.2</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>156</td>
<td>434</td>
<td>37.2</td>
</tr>
<tr>
<td></td>
<td>1.6 0.7</td>
<td>0.4 -3.5c</td>
<td>37.2</td>
</tr>
<tr>
<td>Ages 10-14</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>All Sites</td>
<td>1,855</td>
<td>3,644</td>
<td>63.9</td>
</tr>
<tr>
<td></td>
<td>20.0 0.5c</td>
<td>3.7 -2.0c</td>
<td>46.6</td>
</tr>
<tr>
<td>Bone and Joint</td>
<td>139</td>
<td>526</td>
<td>76.7</td>
</tr>
<tr>
<td></td>
<td>15 0.4</td>
<td>0.5 -1.5c</td>
<td>76.7</td>
</tr>
<tr>
<td>Melanoma of the skin</td>
<td>124</td>
<td>48</td>
<td>55.3</td>
</tr>
<tr>
<td></td>
<td>1.3 0.9</td>
<td>0.0 -3.0c</td>
<td>55.3</td>
</tr>
<tr>
<td>Testis (males)</td>
<td>157</td>
<td>36</td>
<td>88.4</td>
</tr>
<tr>
<td></td>
<td>3.3 1.5c</td>
<td>0.1 -7.6c</td>
<td>88.4</td>
</tr>
<tr>
<td>Brain and Other nervous</td>
<td>172</td>
<td>508</td>
<td>40.6</td>
</tr>
<tr>
<td></td>
<td>1.9 0.3</td>
<td>0.5 -1.2c</td>
<td>40.6</td>
</tr>
<tr>
<td>Thyroid</td>
<td>165</td>
<td>117</td>
<td>21.5</td>
</tr>
<tr>
<td></td>
<td>1.8 1.2c</td>
<td>0.1 -4.3c</td>
<td>21.5</td>
</tr>
<tr>
<td>Hodgkin lymphoma</td>
<td>291</td>
<td>289</td>
<td>21.5</td>
</tr>
<tr>
<td></td>
<td>3.1 -0.7c</td>
<td>0.3 -2.0c</td>
<td>21.5</td>
</tr>
<tr>
<td>Non-Hodgkin lymphoma</td>
<td>152</td>
<td>1,100</td>
<td>21.5</td>
</tr>
<tr>
<td></td>
<td>1.6 1.8c</td>
<td>1.1 -2.1c</td>
<td>21.5</td>
</tr>
<tr>
<td>Leukemia</td>
<td>216</td>
<td>471</td>
<td>21.5</td>
</tr>
<tr>
<td>Acute lymphocytic</td>
<td>111</td>
<td>471</td>
<td>21.5</td>
</tr>
<tr>
<td></td>
<td>1.2 0.6</td>
<td>0.5 -2.3c</td>
<td>21.5</td>
</tr>
</tbody>
</table>

The APC is the Annual Percent Change over the time interval.

Note:
- Incidence and death rates are per 100,000. Survival rates are expressed as percents.
- SEER 9 areas.
- NCHS public use data file for the total US.
- The APC is significantly different from zero (p<.05).
- The APC for 1987-2001 is significantly different from the APC for 1975-1986 (p<.05).
- The APC for 1987-2001 is significantly different from the APC for 1975-1986 (p<.10).
- The difference in rates between 1974-1976 and 1995-2000 is statistically significant (p<.05).
- The standard error of the survival rate is between 5 and 10 percentage points.
- Sites were chosen based on more than 100 SEER incident cases between 1997-2001.
- Statistic could not be calculated.
### Table XXVIII-6

5-YEAR RELATIVE SURVIVAL RATES, 1985-2000*

By International Classification of Childhood Cancer (ICCC) Selected Group and Subgroup and Sex and Age

<table>
<thead>
<tr>
<th>ICCC Group &amp; Subgroup</th>
<th>Ages 0-19 by Sex</th>
<th>Both Sexes by Age</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Total</td>
<td>Male</td>
</tr>
<tr>
<td>All Groups Combined</td>
<td>76.1</td>
<td>74.2</td>
</tr>
<tr>
<td>I Leukemia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>I(a) Lymphoid leukemia</td>
<td>71.1</td>
<td>69.3</td>
</tr>
<tr>
<td>I(b) Acute non-lymphocytic leukemia</td>
<td>79.4</td>
<td>77.8</td>
</tr>
<tr>
<td>II Lymphomas &amp; reticuloendothelial neo.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>II(a) Hodgkin lymphoma</td>
<td>85.0</td>
<td>83.3</td>
</tr>
<tr>
<td>II(b,c,e) Non-Hodgkin lymphoma</td>
<td>75.2</td>
<td>75.0</td>
</tr>
<tr>
<td>III CNS &amp; misc intracranial &amp; intraspinal neo.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>III(a) Ependymoma</td>
<td>63.4</td>
<td>66.3</td>
</tr>
<tr>
<td>III(b) Astrocytoma</td>
<td>78.1</td>
<td>77.8</td>
</tr>
<tr>
<td>III(c) Primitive neuroectodermal tumors</td>
<td>58.5</td>
<td>61.5</td>
</tr>
<tr>
<td>III(d) Other gliomas</td>
<td>58.4</td>
<td>61.6</td>
</tr>
<tr>
<td>IV Sympathetic nervous system tumors</td>
<td>66.0</td>
<td>64.4</td>
</tr>
<tr>
<td>IV(a) Neuroblastoma and ganglioneuroblastoma</td>
<td>65.9</td>
<td>64.5</td>
</tr>
<tr>
<td>V Retinoblastoma</td>
<td>95.4</td>
<td>96.0</td>
</tr>
<tr>
<td>VI Renal tumors</td>
<td>90.1</td>
<td>89.1</td>
</tr>
<tr>
<td>0.1 Wilms' tumor, rhabdoid &amp; clear cell sarcoma</td>
<td>90.7</td>
<td>89.9</td>
</tr>
<tr>
<td>VII Hepatic tumors</td>
<td>50.6</td>
<td>49.3</td>
</tr>
<tr>
<td>VII(a) Hepatoblastoma</td>
<td>60.5</td>
<td>57.0b</td>
</tr>
<tr>
<td>VIII Malignant bone tumors</td>
<td>65.4</td>
<td>63.1</td>
</tr>
<tr>
<td>VIII(a) Osteosarcoma</td>
<td>64.3</td>
<td>61.9</td>
</tr>
<tr>
<td>VIII(c) Ewing's sarcoma</td>
<td>61.5</td>
<td>57.8</td>
</tr>
<tr>
<td>IX Soft-tissue sarcomas</td>
<td>71.4</td>
<td>71.2</td>
</tr>
<tr>
<td>IX(a) Rhabdomyosarcoma &amp; embryonal sarcoma</td>
<td>64.9</td>
<td>64.9</td>
</tr>
<tr>
<td>X Germ-cell, trophoblastic &amp; other gonadal neo.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>X(a) Intracranial &amp; intraspinal germ-cell tumors</td>
<td>89.1</td>
<td>88.4</td>
</tr>
<tr>
<td>X(c) Gonadal germ-cell tumors</td>
<td>79.1</td>
<td>78.3</td>
</tr>
<tr>
<td>XI Carcinomas &amp; other malignant epithelial neo.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>XI(b) Thyroid carcinoma</td>
<td>89.8</td>
<td>96.5</td>
</tr>
<tr>
<td>XI(d) Malignant melanoma</td>
<td>92.5</td>
<td>89.9</td>
</tr>
</tbody>
</table>

* Rates are from the SEER 9 areas. They are based on data from population-based registries in Connecticut, New Mexico, Utah, Iowa, Hawaii, Atlanta, Detroit, Seattle-Puget Sound and San Francisco-Oakland. Rates are based on follow-up of patients into 2001.

b The standard error of the survival rate is between 5 and 10 percentage points.

c The standard error of the survival rate is greater than 10 percentage points.

- Survival rates are relative rates expressed as percents.
SEER Childhood Cancer 1990-2000
5-Year Observed Survival Rates by ICCC Group and Race/Ethnicity
Both Sexes, Under 20 Years of Age

Source: SEER 12 areas.

^ ^^ Hispanic is not mutually exclusive from Whites, Blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.
Hispanic rates exclude cases diagnosed in Detroit and Hawaii.